{
  "name" : "zero.sci-hub.se_6547_b0a0dd0579e203b25060340942f8a0d9_zaidi2017.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Nano-therapeutics: A revolution in infection control in post antibiotic era",
    "authors" : [ "Sahar Zaidi", "Asad U Khan" ],
    "emails" : [ "asad.k@rediffmail.com" ],
    "sections" : [ {
      "heading" : null,
      "text" : "With the arrival of antibiotics 70 years ago, meant a paradigm shift in overcoming infectious diseases. For decades, drugs have been used to treat different infections. However, with time bacteria have become resistant to multiple antibiotics, making some diseases difficult to fight. Nanoparticles (NPs) as antibacterial agents appear to have potential to overcome such problems and to revolutionize the diagnosis and treatment of bacterial infections. Therefore, there is significant interest in the use of NPs to treat variety of infections, particularly caused by multidrug-resistant (MDR) strains. This review begins with illustration of types of NPs followed by the literature of current research addressing mechanisms of NPs antibacterial activity, steps involved in NP mediated drug delivery as well as areas where NPs use has potential to improve the treatment, like NP enabled vaccination. Besides, recently emerged innovative NP platforms have been highlighted and their progress made in each area has been reviewed. © 2017 Elsevier Inc. All rights reserved.\nKey words: Nanoparticle; Antibiotic resistance; Drug delivery; Bacterial infection; Multidrug-resistant strains\nIn spite of marked efficiency of antibiotics, treatments against bacterial infection still have to overcome certain challenges specifically the tendency of bacteria to develop resistance against multiple antibiotics. Multidrug-resistant (MDR) bacteria appear as a perpetual threat due to the fading arsenal of e-cacious antibiotics. Infections caused by bacteria are a serious global healthcare issue with catastrophic consequences. Rapid development of antibiotic resistance in bacteria, coupled with slow and declining development of new antibiotics, has resulted in an arms race between therapeutic development and emergence of antibiotic resistance in bacteria.1 Pathogens gain resistance against antibiotics by different mechanisms like alterations in membrane permeability, multidrug efflux pumps development, deoxyribonucleic acid (DNA) alterations, drug degrading activity of enzymes as well as longer intracellular residence durations, where therapeutic level of drugs cannot be easily achieved,2 consequently requiring higher doses, and repeated administrations of drugs and eventually leading to toxicity or adverse side effects. This complicates compliance and therefore\nDeclaration of interest: The authors report no conflicts of interest. Funding: This study was supported by DST-PURSE Program Phase-II (Promotio ⁎Corresponding author at: Medical Microbiology and Molecular Biology Lab\n-202002, UP, India. E-mail address: asad.k@rediffmail.com (A.U. Khan).\nhttp://dx.doi.org/10.1016/j.nano.2017.06.015 1549-9634/© 2017 Elsevier Inc. All rights reserved.\nPlease cite this article as: Zaidi S, et al, Nano-therapeutics: A revolution in in 2301, http://dx.doi.org/10.1016/j.nano.2017.06.015\nincreases the chances to acquire drug-resistance. Focus of current research is to solve these problems as well as to enhance the antimicrobial efficacy of available drugs by employing drug delivery systems that can be targeted precisely.3–5\nAs stated by Paul Erlich the “concept of magic bullet” that is “the aim of drug targeting is to deliver drugs to the right place, at the right concentration, and for the proper length of time”.6\nIn the last 10 years, nanotechnology has gained significant momentum. Nanomaterials, as antibacterial agents appear very promising and have already achieved much attention and it is anticipated that these might fill those voids where traditional antibiotics recurrently fail.\nUse of nanoparticles (NPs) has increased more than four-fold and current researches are primarily emphasizing the antimicrobial activity of NPs, predominantly against drug-resistant bacteria.7 Moreover, use of NPs as a drug carrier can support and complement traditional antibiotics. Metallic and organic NPs have been found to synergize the killing effect of antimicrobial, antifungal and antiparasite drugs8–10 as well as other agents\nn of University Research and Scientific Excellence) No. SR/PURSE Phase 2/9. ., Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh\nfection control in post antibiotic era. Nanomedicine: NBM 2017;13:2281-\nirrespective of the type of drug and pathogen.11 Moreover, antimicrobial potential of NPs has been extensively explored and nanoscale materials like inorganic ions and polymers are found to have potent antibiotic activity themselves. Is has been proposed that antibacterial effects of NPs are due to three principal mechanisms such as Oxidative stress,12 Metal ion release,13 Non-oxidative stress14 occurring simultaneously, which require multiple simultaneous gene mutations in bacterial cell to develop antibacterial resistance. Therefore, it becomes difficult for bacterial cells to acquire resistance against NPs mediated antibacterial treatment.15\nNPs as delivery systems allow the targeted delivery of drugs as well as sustained and controlled release let them reach the intracellular therapeutic level of drugs. Degradation prior to reaching the target as well as undesirable interactions of drugs can be avoided along with simultaneous optimization of the physicochemical characteristics of the coupled drug. Other advantages of NP delivery systems, includes, enhanced drug solubility, concurrent delivery of multiple drugs, prolonged systemic circulation as validated by many studies.16,17 As a result of this, many NP-based treatments including NPs as vaccine delivery systems have been endorsed to treat variety of infections and several others are currently undergoing through the phases of pre-clinical and clinical tests."
    }, {
      "heading" : "Classification of nanoparticles",
      "text" : "Depending on the material used to produce matrix, NPs have been classified as follows (Table 1)."
    }, {
      "heading" : "Organic nanoparticles",
      "text" : "Among all types, organic NPs are the most studied. These include liposomes, polymeric micelles, polymeric NPs and solid lipid NPs (SLNs). Good compatibility as well as biodegradability are the foremost advantages of using them.46 Their constituent compounds can be easily degraded into biologically tolerated molecules, which are then metabolized via the Krebs cycle. Hence, they have minimal associated systemic toxicity. Furthermore, both hydrophilic and hydrophobic drugs can be carried by them.47 There are certain limitations, like low loading efficacy, drug loss during storage and delivery and they are relatively unstable. Besides, their hydrophilic/hydrophobic characteristics allow their uptake by opsonisation followed by rapid degradation.3,33,48"
    }, {
      "heading" : "Liposomes",
      "text" : "Liposomes are spherical vesicles of phospholipids bilayer and their size varies from 20 nm, in the case of small unilamellar vesicles, to more than 100 nm for large and multilamellar vesicles. Liposomes directly fuse with bacterial membrane and release their contents either into its interior or within the bacterial cell membrane. These are the most extensively explored NPs.49"
    }, {
      "heading" : "Polymeric nanoparticles",
      "text" : "Polymeric NPs are made up of a polymeric matrix, either synthetic or natural polymers with hydrophilic and hydrophobic\nparts. The hydrophobic part forms the polymeric core that holds the cargo and allows polymeric NPs to deliver poorly water soluble molecules, while the hydrophilic part protects the core from degradation. The length of the hydrophobic chain controls the rate of cargo release. The synthetic polymers widely used are polyesters like polylactide (PLA), polylactide–polyglycolide copolymers (PLGA) and polycaprolactones (PCL), and polyacrylates (PCA). Natural polymers include, albumin, alginate or chitosan50,51 Chitosan is most widely used due to its easy modification, muco-adhesive and antimicrobial properties.52"
    }, {
      "heading" : "Polymeric micelles",
      "text" : "Polymeric Micelles are colloidal structures composed of block copolymers. Polymers used in their preparation are PLA, poly(butyl methacrylate) (PBMA), polystyrene (PLS), or poly(ethylene oxide)–poly(propylene oxide) (PEO–PPO). They form a micellar structure spontaneously beyond the critical micelle concentration and the critical micellization temperature. Below which, they are an inert material, and above them the chains become hydrophobic, which results in their aggregation and precipitation.4,53,54 The hydrophobic fragments form the inner core of the sphere, while the hydrophilic ones form the outer shell. The inner core has to be in a solid state in order to incorporate drugs, or else it would result in an instant drug release. Besides, the stability polymeric micelle depends on the drug charge density and the polymer chain length. Size is determined by polymer's chemical structure and is independent of the preparation method which can be an advantage over other type of NPs. Like other organic NPs, polymeric micelles also exhibit low toxicity risk as they disassemble in single polymer chains which can be easily eliminated without any toxicity.4,55"
    }, {
      "heading" : "Solid lipid nanoparticles (SLNs)",
      "text" : "SLNs are colloidal carriers, composed of lipids that remain solid at body temperature, such as acetyl palmitate or salts of myristic acid. SLNs are less toxic, more stable, and are widely available than synthetic polymers NPs. Furthermore, the state of the lipids depends on the conditions of the medium (temperature, pH, etc.), which allows their controlled release, and enhanced efficacy. Due to their unique size-dependent properties, lipid NPs offer the possibility to develop new therapeutics.33,48"
    }, {
      "heading" : "Inorganic nanoparticles",
      "text" : "Inorganic NPs are composed of different inorganic oxides and thus differ in size, shape, solubility and long-term stability. They are prepared by the reduction of the metallic salt (silica/silver/ gold/aluminium/titanium) with a reducing agent56,57 and, depending on the reaction conditions like temperature, pH, reduction time or reducing agent concentration, their characteristics can be modified.38,43,58 For the purpose of drug delivery, selection of the reducing agent is a critical task, as it acts as a link between the NP's surface and the drug or biomolecule of interest. Moreover, loading capacity, drug release, aggregation of NPs as well as the antimicrobial action of drugs is also influenced by the choice of reducing agent.59 Compared with organic NPs, metallic NPs are smaller with more loading capacity, and some with antimicrobial properties can also be used as naked NPs.\nTable 1 Illustration of different types of nanoparticles.\nType Size Characteristics Limitations Applications References\nOrganic Nanoparticle Liposome 20-100 nm Phospholipid\nvesicles, biocompatible, biodegradable, versatile, increases drug efficacy and t herapeutic index and controlled release of drug.\nLeakage of encapsulated drug, uptake and removal by RES, low solubility.\nLong circulatory, offer passive and active delivery of gene, protein, peptide and cytokines, tumor therapy, antisense therapy, DNA vaccination, diagnostic imaging of tumors.\n18,19\nPolymeric Nanoparticles\n10-1000 nm Composed of polymeric matrix, biodegradable, biocompatible, biostable offer complete drug protection, improve drug efficacy and pharmacokinetic parameters, exhibit lower immunogenicity.\nReduced ability to adjust the dose, particle-particle aggregation makes physical handling difficult in liquid and dry form.\nExcellent carrier for controlled and sustained drug delivery. Stealth and surface modified nanoparticles can be used for active and passive delivery of bioactives., cancer therapy\n20,21\nPolymeric Micelles 10-100 nm Block amphiphilic copolymer micelles, delivery of hydrophobic drugs, minimized cytotoxicity, biocompatible, able to accumulate in the target zone based on the enhanced permeability and retention effect.\nLow drug loading and low drug incorporation stability which causes the loaded drug to be released before getting to the site of action.\nLong circulatory, target specific active and passive drug delivery, gene delivery, diagnostic Imaging\n22–24\nSolid – Lipid Nanoparticles\n50-100 nm Lipid based colloidal carriers, controlled release, easy to scale up, enhanced efficacy, economical production, specific targeting and good tolerability\nParticle growth, unpredictable gelation tendency, unexpected dynamics of polymorphic transitions and lower incorporation due to the crystalline nature.\nAdjuvant for vaccines, cancer chemotherapy, delivery of genes, peptides and proteins, targeted brain drug delivery, treatment of malaria and tuberculosis.\n21,25\n(continued on next page)\nTable 1 (continued)\nType Size Characteristics Limitations Applications References\nInorganic Nanoparticles Iron-Oxide Nanoparticles 1-100 nm Unique\nphysicochemical properties, Stability for the adsorption of biomolecules, high biocompatibility, intrinsic magnetic properties, highly regulated motion in bloodstream due to the applied magnetic field.\nNaked iron oxide NPs have high chemical activity, tends to aggregate, oxidized by air resulting in loss of magnetism and dispersibility.\nNano source of heat for hyperthermia in infected tissues, biosensing, drug carriers, detection of hemoglobin, magnetic resonance imaging,detection of bacteria, cancer therapy immobilization of biomolecules, jet printing.\n26–29\nGold Nanoparticles (AuNP)\n1-100 nm Unique light scattering and optoelectronic properties, show plasmon resonance phenomenon, high surface area to volume ratio, stability and biocompatibility, easy surface modification.\nWeak optical signal, lower biocompatibility and tumor target efficacy, acute and chronic toxicity, non biodegradability.\nTargeted delivery of drugs, DNA, and iRNA, hyperthermia therapy, biomarkers detection in the diagnosis of cancers, heart diseases and infectious diseases, biological imaging, transmission electron microscopy, cancer therapy.\n30–33\nSilver Nanoparticles (AgNP)\n1-100 nm Bactericidal and fungicidal properties, broad spectrum activity, enhanced efficacy of drugs, high surface to volume ratio, unique optical, electrical, and thermal properties, catalytic activity, enhanced Raman scattering.\nAllergies, cytotoxicity, accumulation in body and skin causes skin discolouration as well as neurologic, renal, or hepatic complications\nAntimicrobial coatings, biosensors, biological imaging, bio labeling, cardiac devices, as antiseptics in eye drops to prevent conjunctivitis, in dermatology, in bone prostheses, reconstructive orthopedic surgery, to treat immunologic and inflammatory diseases and in dental caries.\n32,34,35\nTable 1 (continued)\nType Size Characteristics Limitations Applications References\nSilica Nanoparticles 20-400 nm Highly porous, tunable pore size, low toxicity, high target selectivity, high loading efficiency, biostability, ability to be functionalised with a range of molecules, easy to synthesize and modify homogenous distribution of guest molecules in porous space,free dispersion throughout the body.\nSilanol groups interact with phospholipids of the red blood cell resulting in hemolysis, metabolic changes induced leads to melanoma promotion, low biodegradability.\nDrug delivery, gene transport, thernostics, biomedical imaging contrast agents, ablative therapy sensitizers, biomarking, biosignal probing,\n36,37\nCopper Nanoparticles 2–350 nm Antimicrobial, antifungal, anti-inflammatory and antiproliferative, low production cost and high conductivity.\nToxicity, agglomeration and rapid oxidation\nDelivery systems, antimicrobial coatings,\n32,38\nQuantum Dots (QDs) 2–9.5 nm Colloidal semi- conductor nano-crystal with unique properties like, wavelength tenability, bright fluorescence, narrow emission, broad UV excitation and high photostability, resistant to degradation, tunable size.\nDifficulty in diffusion across biological membrane, cytotoxicity, extended lifetime and low biodegradability, may stay undetectable due to their low transmittance.\nLong term multiple color imaging of liver cell; DNA hybridization, immunoassay; receptor mediated endocytosis; labeling of breast cancer marker HeR 2 surface of cancer cells, bacterial detection and identification.\n29,39,40\nOther Nanocarriers Carbon Nanotubes 0.5–3 nm diameter\nand 20–1000 nm length Third allotropic crystalline form of carbon sheets either single layer (single walled nanotube, SWNT) or multiple layer\nCause inflammatory and fibrotic reactions, difficult to manage due to small size, very expensive to produce, cytotoxicity, lack of solubility in aqueous media,\nAs implants without host rejection response, as carrier for gene, drug and, peptide delivery, as bone substitutes, tissue engineering, molecular imaging.\n41–43\n(continued on next page)\nTable 1 (continued)\nType Size Characteristics Limitations Applications References\n(multi-walled nanotube, MWNT). These crystals have remarkable strength, elasticity, low weight and unique electrical properties (conducting, semi conducting, or insulating)\nNanobubbles 200-500 nm Are gas filled cavities present in aqueous solution, long lifetime in liquid owing to its negatively charged surface, and its high gas solubility into the liquid due to its high internal pressure, highly stable, have a lower buoyancy and remain suspended in liquids for an extended period of time, release is stimulated by ultrasound.\nConsiderable liver and kidney toxicity and cytotoxicity\nTheranostics, targeting drugs to specific sites, sterilization using ozone gas, oxygenation of hypoxic tissues diagnostic aids, malaria detection.\n44,45\nInorganic NPs get distributed in the spleen, liver and lymph nodes.56,60 Therefore, they are mainly used for treating illnesses related to reticuloendothelial system (RES).They exhibit problems of aggregation, accumulation and metabolization. Elimination from the body is generally through bile, which is a slow and saturable pathway, so they may remain accumulated for long time in the body.45,56,60 Nevertheless, this depends on the type of metal being used, because some metals have well-established physiological routes of absorption and elimination.61\nMoreover, their interaction with proteins can produce liver or skin damage, increased spleen weight, alterations in RBCs and inflammation. The release of toxic ions and the stimulations of (reactive oxygen species) ROS and inflammatory cytokines intracellularly can produce immunotoxicity, cytotoxicity and genotoxicity, both in healthy and infected cells. Moreover, chronic toxicity such as nephrotoxicity, hepatotoxicity or\npulmonary toxicity, can be produced by the accumulation of metallic NPs in these tissues. In any case, toxicity can be reduced by lowering NPs concentrations or chemical transformations, like changes on the surface of NPs, such as sulfidation or electrostatic surface charge as well as modifications in size.55"
    }, {
      "heading" : "Iron oxide nanoparticles",
      "text" : "Iron oxide NPs coated with antibodies targeted against pathogen have been widely used to isolate bacteria from human blood samples under the effect of magnetic field.62,63 Recently, this technique coupled with microfluidic technology has resulted in high-throughput bacterial detection under various clinical settings.64,65 For in vitro diagnosis, iron oxide NPs with a diameter of 21 nm are linked with a DNA hybridization technique to enhance the capturing of bacterial 16S ribosomal\nribonucleic acid (rRNA) with a miniaturized micro-NMR system, resulting in specific and quick pathogen profiling in clinical samples.66"
    }, {
      "heading" : "Gold nanoparticles (AuNP)",
      "text" : "Strong absorption of AuNPs in the near-infrared region (NIR), in addition to their flexible chemical and physical properties, make them suitable candidate for a large number of biomedical applications.67 Colloidal AuNP having resilient properties like bioconjugation surface for molecular probes, strong light scattering properties and also, they change their plasmon resonance spectrum upon aggregation. This phenomenon is of paramount importance for the detection of bacteria-specific DNAs, live bacteria and proteins. For example, AuNP have been designed in such a way that they precisely cross-link with switchable linkers, which break in the presence of target subjects. As a result, this design amplifies the pathogen-induced NP aggregation-dispersion process and allows visible detection of bacteria at a concentration of 100 CFU/ml. Besides, AuNP can non-specifically quench fluorescent molecules. Based on this phenomenon, a fluorophore displacement strategy has been exploited for bacterial detection.68,69"
    }, {
      "heading" : "Silver nanoparticles (AgNP)",
      "text" : "AgNPs are the most widely explored and have gained attention due to their exceptional antibacterial properties and broad antimicrobial spectrum. Advantage of using them is that, they kill bacteria through different mechanisms. Therefore, it is difficult to developed resistance against them.70 The results indicate that AgNPs show antibacterial activity without differentiating between resistant or susceptible strains.71 These NPs attach to the cell membrane, damages it and increases its\nporosity. Additionally, once inside the cell, silver ions generate free radicals and increases ROS level which inhibit respiratory enzymes and evoke inflammatory responses, ultimately inducing apoptosis.72,73 In this way, AgNPs have been found to exhibit higher antimicrobial activity than antibiotics like gentamicin or vancomycin against Pseudomonas aeruginosa and Methicillinresistant Staphylococcus aureus or MRSA.74"
    }, {
      "heading" : "Quantum dots (QDs)",
      "text" : "QDs emerged as a promising class of fluorophores for bacterial detection. These are metallic NPs with a core made of semiconductor materials like cadmium or zinc. They have unique optical properties that further enhance the possibilities of detecting and tracking them. Hence, they can be observed by fluorescence resonance over extended periods of time.75 Some strategies have been explored to further increase the sensitivity of QD-based bacterial detection systems. For example, the binding affinity of QDs coated with (zinc II)-dipicolylamine coordination complexes, a bacterial ligand, has been shown to correlate to the size of the QD. Based on this observation, QDs with tailored sizes have been designed to differentiate different mutants of the same bacterial species.76 Moreover, recently photoexcited (QDs) were found to kill a number of MDR bacterial clinical isolates, such as MRSA, carbapenem resistant Escherichia coli, and extended-spectrumβ-lactamase producing Klebsiella pneumoniae and Salmonella typhimurium. The killing effect is entirely controlled by the redox potentials of the photogenerated charge carriers that inhibit MDR bacteria through targeted interactions with the cellular redox environment quantum dots.1 Engineered QDs with integrated imaging, targeting and therapeutic functionalities serve as excellent materials to deliver drugs. As a result of their high drug loading capacity and their ability to cross various\nbarriers, QDs are being employed for the intracellular delivery of different types of peptides, drugs and nucleic Acids.77"
    }, {
      "heading" : "Other inorganic nanoparticles",
      "text" : "Copper, zinc, platinum, aluminium, palladium, or titanium are some other metallic NPs that have also been designed. These can be used either as naked NPs or as carriers, enhancing the therapeutic effect owing to their antimicrobial and/or magnetic properties. Zinc oxide nanoparticles (ZnO-NP) with excellent antibacterial activity were used against a wide range of bacteria. But the limitation of aggregation makes them toxic against mammalian cells.78 Due to their antibacterial and antifungal properties, Copper NPs are also gaining attention although like other metals, the accumulation of copper is also toxic. But unlike silver or gold, there are copper-transporters in the body that regulate copper homeostasis.79 Others, like calcium fluoride nanoparticles (CaF2-NPs), are found to have anticariogenic potential against S. mutans which is due to the adherence of NPs on the tooth surface and the sustained release of fluoride ions from CaF2-NPs, as a result, it not only suppresses virulence traits of S. mutans but also promotes remineralization.80"
    }, {
      "heading" : "Other nanocarriers",
      "text" : "New nanosystems that have recently been developed are one of the most popular technologies involving carbon nanostructures, such as nanotubes. Their geometry, thermal, electrochemical and spectroscopic characteristics, along with the wide variety of structures and surface modifications, make them a good option for their application in Nano medicine. They can easily interact with microbial surface due to their small size, disrupting its membrane integrity, metabolic processes and morphology.75,81–83 Other novel nanocarriers are nanobubbles, wrapped by a polymer, protein and/or surfactant, these are gas-filled colloids. The composition of the shell influences their stiffness and resistance to rupture, as well as the recognition and clearance by the RES.84"
    }, {
      "heading" : "Antibacterial mechanisms of nanoparticles",
      "text" : "The elevated use of NPs in the field of medicine has raised the interest of many researchers to further explore the potential antibacterial mechanisms of NPs, predominantly the metallic NPs. It has been suggested that NPs antibacterial activity requires contact with bacterial cells thereby damnifying them followed by crossing of NPs through the bacterial membrane, interfering with cellular components and metabolic machinery and ultimately leading to cell death. Following are the mechanisms that are often proposed in current research as the leading cause of antibacterial action of NPs such as: oxidative stress, metal ions release, and non-oxidative mechanisms as illustrated in Figure 1.85,86"
    }, {
      "heading" : "Oxidative stress",
      "text" : "Key mechanism involved in NP's antibacterial activity is ROS-induced oxidative stress. ROS (reactive oxygen species) is a generic term that represents reactive molecules with high positive redox potential. By reducing oxygen molecules present in the microenvironment, different types of ROS are produced by different NPs. The four types of ROS produced are 1) hydrogen peroxide (H2O2), 2) hydroxyl radical (·OH), 3) singlet oxygen (1O2), and 4) superoxide radical (O\n−2), each exhibiting variations in its dynamics and activity.87 For instance,O−2 is generated in case of magnesium and calcium NPs, whereas ZnO-NP can create oxidative stress by producing H2O2 and ·OH only. However, generation of all four types of ROS has been proposed in case of copper oxide nanoparticles (CuO NPs). It has been found that cell membrane permeability changes primarily due to oxidative stress, once inside the cell, intracellular ROS causes loss of membrane integrity, attack proteins and enzymes that are crucial for cell morphology as well as for maintaining normal physiological processes of bacterial cells.85 Moreover, it causes elevated expressions of oxidative proteins that leads to cell apoptosis and death.88"
    }, {
      "heading" : "Metal ions release",
      "text" : "Slowly releasingmetal ions frommetal oxide NPs gets adsorbed on the cell membrane, and interact with amino (−NH), mercapto (−SH) and carboxyl (−COOH) groups present in nucleic acids and protein thereby disrupting and destroying cell morphology as well as interfering with the normal physiological processes. However, metal ionmediated killing is insignificant due to the pH inside lipid vesicles, which results in weak antimicrobial activity. Therefore, metal ions have only small contribution in NP's antibacterial activity. It has been shown that released silver ions can bind to cell membrane and destabilizes the membrane potential that results in proton leakage, therefore disruption of cell morphology.89,90"
    }, {
      "heading" : "Non-oxidative mechanisms",
      "text" : "Non-oxidative mechanism involves the interaction of NPs with the cell wall. Multi-layered structure enveloping the bacterial cell serves as a defensive barrier against unpredictable and often hostile environment. Gram-positive and Gram-negative bacteria vary in terms of the cell membrane components and structures, therefore produce different adsorption pathways for NPs.91 Lipo-polysaccharides (LPS) along with phospholipids which forms the outer covering of Gram negative bacteria are responsible for its highly negatively charged cell surface that attracts NPs. In contrast to this, in Gram positive bacteria, teichoic acids linked with plasma membrane or peptidoglycan imparts this negative charge to the surface. Phosphate present in teichoic acids attracts and distributes NPs along the molecular chain of phosphate, avoiding any aggregation. Moreover, it has been validated that NPs antibacterial effect is more pronounced for Gram-positive bacteria than Gram-negative bacteria. Cell wall of Gram-negative bacteria serves as a penetration barrier for the entry of NPs due to its non-porous nature. However, cell wall of Gram-positive bacteria is relatively porous that allows foreign molecules to penetrate, followed by the formation of covalent links with neighboring proteins and components of cell wall.92 Such connections restrain enzymes and proteins involved in cell metabolism thus disrupting normal functioning of bacterial cell.85 SEM studies have shown that the treatment with TiO2 NPs causes increased volume of bacterial cell, resulting in formation of honeycomb like structure that eventually results in cytoplasmic leakage.93 Also, it can cause aggregation of bacterial cells resulting in inactivation due to compression.94 Furthermore, synthesis of proteins as well as DNA of bacterial cells are also hindered by NPs for example it was found that CuO NPs interfere with electron transport chain of bacterial cells, nitrogen metabolism, and transport system by altering the expressions of key proteins.95 Compression and degeneration of bacterial cell DNA followed by its fragmentation was found as a result of activity of TiO2 NPs. 93"
    }, {
      "heading" : "Nanoparticles: As carrier of antibiotics",
      "text" : ""
    }, {
      "heading" : "Distribution of nanoparticles",
      "text" : "The surface characteristics, size and the shape of a NP are the critical factors that affect their bio-distribution in-vivo. Small\nsize NPs are slowly up taken by phagocytic cells and therefore undergo faster distribution in the body due to their rapid dissolution. Also, NPs of smaller size are found to have better drug loading efficiency and enhanced antimicrobial effect and thus lower MIC (minimum inhibitory concentration). However, particles smaller than 5 nm undergo rapid clearance from circulation either by extravasations or through renal clearance. Bone marrow, liver and spleen are the main sites of accumulation of particles, having diameter in the range of nanometer to ~15 μm. NPs of the range ~ 10 nm to ~15 μm show behavior variations particularly in terms of bio-distribution, and their uptake decided by the cell type. Mechanical filtration in capillaries eliminates particulate matter (larger than ~15 μm) from the circulation. Depending on the size of the dose, it may also leads to lethality. Therefore, the size of NP is carefully decided depending on diseased target as well as the drug characteristics.96 Under normal circumstances, NPs filtered by sinusoids in the spleen, are eliminated from the circulation by the action ofRES.Besides, in liver, kupffer cells being a part of theRES, also have considerable contribution in NPs clearance.97 Adsorption of specific proteins called opsonisation, to the particle surface in the body causes their accumulation in the cells of the RES, that can be altered by the modifying their surface properties. This process of opsonisation starts as soon as plasma proteins come in contact with NPs.96,98,99 Methods to overcome the undesirable attributes of opsonisation are focusing on retarding this process by making the surface of NP more hydrophilic or by removing charges present on the surface thereby neutralizing it.100,101 As indicated by current findings that particle shape have also a considerable contribution in controlling important aspects of this phenomenon. Taking into account the rate of internalization, close connection between shape and the size of the NPs was seen. Particles having same size but dissimilar shapes have different rates of internalization and vice versa. Also extent of interactions between cell and the NP has a key contribution that can stimulate or inhibit their internalization.102,103 The zeta (ζ)-potential is another important factor that influences bio-distribution, uptake by cells and the antimicrobial effect of NPs. Charge present on NPs regulate their interactions with cell membrane, as well as with the proteins present in mucosa, tissues and blood and these interactions control the type and quantity of protein adsorbed; for how long it remains adsorbed, endocytosis mechanisms and bio-distribution. These interactions further modify cell membrane permeability and cytoplasmic flow thus disturbing the metabolism of the cell.55,104,105 In addition to other properties, hydrophobic molecules and particles are more readily taken up by cells, since hydrophobicity leads to better interactions with the opsonins, complement system as well as lipids present in cell membrane. In contrast to this, hydrophilic exhibit fewer interactions therefore are retained longer in the body.Moreover mass and charge densities of bactericidal molecules increase when coupled with NPs leading to their improved therapeutic index.106–108"
    }, {
      "heading" : "Targeted drug delivery",
      "text" : "Vancomycin strongly inhibits Gram-positive bacterial infection, although it produces side effects like ear and kidney toxicity. One way to overcome the problem of toxicity would be preventing delivery of drugs to untargeted or undesired sites thereby avoiding the adverse effects as well as increasing the\nTable 2 (continued)\nNanoparticle Encapsulated drug/compound\nTargeted microorganism Conjugation/Coating Mode of study References\nSilver quantum dots Zinc - rifampicin complex\nMycobacterium smegmatis and Mycobacterium bovis\nTransferrinconjugation\nIn-vitro and Ex-vivo\n56\nMulti-Walled Carbon Nanotubes _____ Methicillin-resistant Staphylococcus aureus\nIgG conjugation\nIn-vivo 178\nSingle walled carbon nanotubes with antimicrobial peptide\nAntimicrobial peptide\nStaphylococcus aureus, Streptococcus pyogenes, Salmonella enterica and Escherichia coli.\nSilver coating\nIn-vitro 179\namount of drug, delivered to the infected site. NPs as a carrier appear as a platform through which such problems can be circumvented. For instance, vancomycin conjugated mesoporous silica NPs, can selectively kill Gram positive bacteria without affecting the neighboring cells.109 Passive targeting and active targeting represent the two ways through which NP-based targeted drug delivery can be achieved. Passive targeting involves augmented permeation followed by retention at the infection site. Accumulation of bacterial components at the infection site causes enhanced vascular permeability which subsequently results in feasible passive targeting. For example teichoic acid and LPS, components of cell wall of Gram-positive bacteria and Gram-negative bacteria respectively, stimulate various mediators involved in inflammatory reactions that ultimately causes increased permeability.110 Immune cells are also activated by bacterial components, which then interact with vascular endothelium through vascular and inflammatory mediators resulting in barrier dysfunction, gap expansion and elevated permeability.111 Besides, dysfunctional lymphatic drainage is another important feature that potentiate accumulation of NPs at the site of infection. These findings suggest that, as a result of bacterial infection, phenomenon of increased permeation and retention (EPR), can be effectively harnessed for NPs mediated targeted delivery of drugs.112 In fact, selective accumulation of both uncoated and PEGylated liposomes at Staphylococcus aureus (S. aureus) infected site, has been reported. Similarly, superparamagnetic iron oxide nanoparticles (SPIONs) have also been found to accumulate selectively at the S.aureus infected soft tissue of rats and lungs of mice.110\nUnder physiological conditions, pathogenic bacteria maintains a negatively charged surface which can be utilized for efficient bacterial targeting using cationic NPs.113,114 In HIV infection positively-charged proteins (viral protein gp120) are expressed by infected cells, and therefore anionic NPs provide better targeting.115 Another strategy to target bacteria is active targeting. Active targeting is based on recognition of some specific ligarnds/molecules on infected cells. This can be achieved by modifying surface of NPs thereby allowing NP-based drug delivery system to selectively target the diseased sites. In Active targeting, receptor, temperature or magnetic properties can also be targeted. Bactericidal polymers and peptides coupled with different NPs have been employed to target wide range of bacteria.110,116 Moreover, antimicrobial peptides (AMPs) are short cationic peptides (10–40 amino acids)\nthat are commonly used for effective targeting of cells.117,118 These vary in terms of their nature and sequence as well as antimicrobial property.118 TAT (trans-activating transcriptional activator), penetratin, transportan, polyarginine and MPG are some of the commonly used peptides employed to treat infections.56\nGram-positive and gram negative bacteria being selectively targeted as a result of conjugation of vancomycin molecules on the surfaces of different NPs. Molecular orientation, surface density, and length of the spacer used in conjugation are some of the important aspects to be carefully selected for efficient targeting of such small molecules. 119 Ligands like mannose-specific or fucose-specific lectins are also being used to target bacteria,120 these, when conjugated with polymeric NPs show preferential binding to carbohydrate receptors present on the surface of Helicobacter pylori (H. pylori).121 Single-domain antibodies122 and bacteriophage tail spike proteins,123 also provide site specific targeting and delivery, when conjugated to the surface of NPs. Glycosylation of the surface is also drawing attention of many researchers to target cells like non-parenchymal cells of the liver or hepatocytes.124 Besides, if central nervous system (CNS) is the target, methods favoring the passage across the brain blood barrier (BBB) are of great importance, like insulin or transferrin receptors when coupled with NPs help them to cross the BBB.125 Also, transferrin or insulin receptor alpha monoclonal antibody (83–14MAb) enhances their uptake bymany folds as compared to free drug or uncoated NPs.126 Moreover, apolipoproteins or polysorbate 80 (which adsorb apolipoproteins) can be used to selectively deliver drug molecules to brain through lipoprotein receptors.125 It has been observed that polysorbate 80-polymeric NPs leads to 35% higher uptake and faster delivery to the brain than uncoated NPs.127,128\nBacteria can even survive when ingested by phagocytic cells like macrophages thus evade the immune system as well as the bactericidal activity of drugs.129 Macrophages spontaneous scavenging feature causes preferential uptake of NPs130,131 and their chemotactic movement helps in drug delivery to the site of infection.132 Consequently, instead of targeting bacteria, antibacterial NPs can be targeted to macrophages. This appear as an appealing strategy particularly against intracellular infections.3 Moreover ligands like mannose, O-steroyl amylopectin, maleylated bovine serum albumin are being successfully used to further enhance NPs uptake by macrophages.133,134 Furthermore, high-affinity oligonucleotide ligands like aptamers represent another targeting\nmoieties. These high-affinity ligands can be developed against almost any target due to advanced selection techniques which design aptamer according to specific bacterium, therefore elevated specificity, binding affinity can be obtained135,136 as shown in Fig. 2."
    }, {
      "heading" : "Controlled drug release",
      "text" : "Since the burst release can be helpful and may be more effective than prolonged delivery, there is a need for stimulus-responsive delivery systems, which remain dormant for extended periods, but release cargo upon a certain trigger such that the drug can only be extracted when required, in this manner uncontrolled leaching of drugs can also be avoided. As the nature of stimulus changes, structure of some polymers can be altered in a reversible way resulting in controlled delivery.53 Environmentally responsive NPs have also been designed to further enhance therapeutic efficacy of antimicrobial NPs, which become active only when activated by certain signals at the diseased site. Physical signals like ultrasound, electric field, temperature, magnetic field or physiological conditions like acidic or basic pH, ionic strength of the medium, redox potential, presence or absence of specific molecules, enzyme activity are some of the conditions that can be efficaciously utilized to design stimulus responsive drug delivery systems.137 For instance, to deliver drug along the gastrointestinal (GI) tract, NPs stimulated by pH gradient have been formulated. NPs that respond to acidic conditions of the endolysosomal compartments have been designed to treat infections at intracellular level. Additionally, enzymatic activities of bacteria, like secretion of toxins can also be used to stimulate the release of encapsulated antimicrobial\nagents at the infected site.110 Controlled drug release through pH-sensitive delivery systems has been prepared by modifying nanoporous silica nanoparticles (NPSNPs) with poly(4-vinylpyridine) using a bismaleimide as linker in which drug chlorhexidine was loaded. At physiological pH, the polymer blocks pore openings for preventing the release of cargo molecules thus serving as gate keeper. As soon as the pH becomes acidic, which generally occur during a bacterial infection, protonation of the polymer strains takes place, polymers get straightened up due to electrostatic repulsion resulting in the opening of pores and eventually cargo is released.138\nCharged NPs when adsorbed on liposomal surface, reduces surface tension as well as create steric repulsion that prevents fusion of liposomes ultimately leading to their stability.139–141 Using this strategy, pH-sensitive drug release can be achieved by employing ionic liposomes coupled with molecules of opposite charge. For stimulus dependent NP's binding and detachment, charge density as well as the charge of liposomes and the stabilizers should be carefully decided. Liposomes having positive charge when coated with carboxyl modified AuNPs avert their fusion activity while at acidic pH, AuNPs stabilizers get detached resulting in the fusion of liposomes with bacterial membrane. This approach is used to treata number of skin infections that thrives in acidic pH like Propionibacterium acnes (P. acnes).142 For controlled and well-regulated viscoelasticity and drug release, a hydrogel form of NPs-stabilized liposomes have been designed which also preserve the structural integrity of liposomes thus can effectively be used for topical applications.143 Another example of pH responsive drug\ndelivery, polymeric NPs, composed of poly(L-histidine), PLGA and polyethylene glycol (PEG) capable of switching surface charge. Under physiological conditions, they remain negatively charged, but attain positive charge under acidic conditions as imidazole groups present in its structure gets protonated, resulting in improved binding and delivery at infected site.144 Heparin and chitosan are also being used to form NPs stimulated by basic pH, thus can be employed against different gastric pathogens like, H. pylori.145,146"
    }, {
      "heading" : "Nanoparticles clearance",
      "text" : "As soon as the drug is completely released, cell must get rid of NPs. But the charge and size of most NPs, especially the inorganic ones, preclude their efficient clearance as intact NPs. Moreover, NPs do not undergo biodegradation into biologically benign components and thus exhibit prolonged tissue retention eventually leading to amplified toxic effects. Therefore designing a NP with optimal elimination properties is also one of the important aspects for successful NP mediated treatment. Opsonisation of NPs by serum proteins is controlled by charge and size of the NPs. As a result of opsonisation, effective size and diameter of the NP is altered, which is referred to as in vivo hydrodynamic diameter (HD). It can be appreciably more as compared to the in-vitro diameter.147 The vascular endothelial layer that serves as dynamic and semi-selective barrier, controls transport of compounds between vascular compartment and extravascular space. In general, endothelium have pore size of 5 nm therefore, nanoscale particles having HD smaller than 5 nm gets equilibrated with the extravascular extracellular space (EES), conversely bigger particles remain in circulation for extended periods due to their slow movement across the endothelium. Due to the role of lymphatic system in the elimination of larger molecules, endothelial layer of lymphatic vessel provides better permeation as compared to the vascular endothelium. Particles having diameter of 6 nm or smaller are free to move in and out of the lymphatic vessels.148 Kidney rapidly remove molecules from the vascular compartments with minimal catabolism or breakdown to avoid the possible side effects, therefore clearance of NPs from body through renal excretion is an ideal pathway to avoid toxicity. Molecules reaching glomerular capillary bed, either undergo filtration into proximal tubule through the capillary walls of glomerulus, or they are retained in vascular compartment.149 HD plays an important role in renal clearance as there is an inverse relation between HD and the rate of glomerular filtration. Particles having HD less than 6 nm are efficiently filtered while particles larger than 8 nm do not experience glomerular filtration. For particles lying in the range of 6–8 nm, their filtration is dependent on particles size as well as the charge. For instance, quantum dots having HD equal to8.65 nm, do not undergo filtration and are rather up taken by RES.147 Renal filtration rate is decided by charge on the molecule, due to two reasons, (i)Amplified interactions between charged particles and serum proteins, results in better protein adsorption and therefore elevated HD,148 (ii) Potential interactions between charged particles and charged capillary walls of the glomerulus.149 Neutralization via PEGylation of the NP surface, significantly\ndecreases renal filtration as a result of reduced interaction of neutral particles with serum protein. Zwitterionic coatings also reduce HD by obstructing the process of protein adsorption. Dependency of glomerular filtration rate on the nature of charge of molecule was evaluated by taking molecules of same size having different charges. Cationic molecules filtered most readily on passing through the glomerular apparatus, followed by molecules without any charge, while anionic molecules have been found to have the lowest filteration rate.147,148 Particles (in the range 10 nm–20 nm) excluded from renal filtration, are eliminated through hepatobiliary system. Liver serves as a site for catabolism as well as perform biliary excretion. Moreover, it plays a significant role in the clearance of foreign particles through phagocytosis. Particles phagocytized by kupffer cells undergo intracellular degradation for efficient elimination. Remaining particles that successfully escape the degrading activity of kupffer cell are eventually retained in the body for prolonged periods.150 Easily modifiable surface chemistry and size of certain NPs, allow the alteration of their in-vivo kinetic properties in a manner so as to create NPs with optimum clearance characteristics and thereby reducing the associated toxicity, for example PEGylation that refers to the process of attaching PEG (which is found to have very few interactions with intracellular proteins), is one of the most widely employed approaches that results in improved pharmacokinetic behavior of the NPs.148,151\nTable 2 further describes recent studies on, NP mediated treatment against bacterial infections."
    }, {
      "heading" : "Nanoparticles as vaccine",
      "text" : "Prophylactic vaccination has turned out to be one of the most powerful and effective interventions in the field of medicine to prevent and treat variety of infections. Recombinant or purified proteins obtained from the corresponding pathogen are being used in contemporary vaccines. They have been found to produce feeble immune response and are not sufficiently effective in the long-term.180 Majority of existing vaccines predominantly focuses on generating opsonizing or neutralizing antibodies, an approach that is inefficient against many pathogens.181 Vaccine formulation is further obstructed by the lack of knowledge of highly complicated immune system of the human body.182 Approaches to overcome such difficulties like modulation of human immune system through biocompatible-nanomaterials appear as a promising strategy for more effective and safer vaccine development.183,184 Most of these NPs vaccine delivery systems are based on polymers that encapsulate chemically coupled protein antigens.185\nNP vaccine delivery system appear as a potential solution to the conundrums associated with traditional vaccines like unwanted distribution in the body, instability and toxicity linked with soluble compounds.186,187 NP vaccine delivery systems are found to have multi-fold advantages over traditional vaccines like; 1) encapsulated antigens are more stable and remain protected from the hostile environment, 2) surface modifications of NPs with functional moieties and targeting ligands allow organ and cell-specific targeting, 3) co-encapsulation of antigens\nand immunostimulatory agents enhances potency as well as the immunogenicity of vaccines,4) particles having multivalent presentation of antigens on their surface promote crosslinking of B cell receptors leading to amplified humoral immune response, 5) antigen can be readily phagocytosed and processed by antigen presenting cells (APCs), resulting in enhanced immune response, 6) NPs designed for cytosolic delivery, enhance cross-presentation and major histocompatibility complex-I(MHC-I) presentation of antigens, thus increasing cytotoxic T-cell lymphocyte (CTL) responses as illustrated in\nFigure 3.188,189 For instance Zinc NPs (ZNPs) exhibit good adjuvant potential, hence can be served as a vaccine transporter. ZNPs complexed with ScaA antigen derived from Orientia tsutsugamushi is an autotransporter protein, could induce many folds stronger protective immunity responses thus resulting in high titer values of antibody produced against O. tsutsugamushi that causes scrub typhus, a lethal disease more prevalent in Asian-Pacific region, South Korea and China.185\nVarious national and international organizations are committed to formulate an effective and safe vaccine against Plasmodium falciparum that causes malaria. Recombinant or virus derived vaccines against malaria are not sufficiently effective in long term. Self-assembling protein nanoparticle (SAPN) has already been proved effective in a rodent model against infection caused by P. berghei. Moreover, P. falciparum epitopes encapsulated in SAPN is now been checked in-vitro to be used in human subjects in future against malaria. The SAPN have been found to induce strong responses of cellular and humoral immunity against sequences derived from the epitopes of circumsporozoite protein (PfCSP) of P. falciparum.190\nWith the advancements in the field of NP engineering, fabrication techniques like facile spray-drying process,191 PRINT technology based on soft lithography192,193 and layer-by-layer assembly194 have been developed to design better NP-based vaccine delivery systems as well as to improve antigen loading. NPs coated with natural cellular membrane were shown to be effective in keeping membrane-damaging toxins away from their cellular targets.195,196 This toxin-detainment approach, when used to deliver antigens like α-hemolysin obtained from staphylococcus to APCs could produce better and long lasting immunity than heat-denatured toxins.197 Reliable antigenic presentation, thereby minimizing the risk of toxin associated adverse effects, could also be ensured by this strategy and it is being focused to design better toxoid vaccine without compromising the efficacy or the safety. In addition to delivering antigens, NPs can concurrently carry adjuvant thus imitating natural infections consequently leading to boosted immune response.198,199 Immune response comparable to that induced by soluble antigens could be produced when antigens along with toll-like receptor (TLR) ligands, DNAs, RNAs, carbohydrates are delivered using NPs, at considerably curtailed dosages.55,180 Moreover, to further enhance the immune responses, NPs permits programmable presentation like instead of single adjuvant, different TLR agonists combinations are taken along with the antigen. These are concurrently coupled with NPs to imitate the combinatorial TLR activation that takes place when exposed to natural infections, thus leading to amplified immune response200 [201–202].\nTargeted vaccine delivery allows safer and more effective immune responses, for example, a cationic nanogel encapsulating subunit fragment derived from the neurotoxin of Clostridium botulinum results in persistent and prolonged adherence of antigen to the nasal epithelium and consequently causing better uptake and presentation by dendritic cells present in the mucosa. This platform, along with augmented mucosal and systemic immune responses, averts toxic antigens from being exposed to upper respiratory tract and the CNS [203]. Furthermore, antigens encapsulated in NPs responding to the pH gradient along the GI tract remain protected inside the NPs in the stomach but are released on reaching lower GI tract followed by their translocation through the intestinal epithelium [204]. To selectively target antigen-transcytosing microfold cells (M cells) for better immune response similar strategy can be adopted [205]. Besides, NPs mediated vaccine delivery can specifically target lymph node, which is the primary site of action for initiating adaptive immunity, where T and B cells that are the major cell types involved in a humoral immune response, meet antigen or antigen-loaded APCs.195 Smaller NPs have been observed to deliver more readily to lymph nodes [206] as compared to larger particles [207], indicating the importance of size optimization to target the lymphatic system. NPs allow reduced amount of antigen required to stimulate immune response and also reduced dosing of booster. Another critical aspect to be considered for desired immune response is, the entry of adjuvant into the cell must be either before or should be concomitantly delivered with antigen [208]. Moreover, by employing NPs, administration of vaccines through more patient-friendly pathways likeoral, transcutaneous or intranasal can be achieved. Mucosa represents the foremost line of defense, therefore NPs encapsulated mucosal vaccines act as a shield against different infections to protect the host even prior to the entry of pathogen into the systemic circulation.49 Subcutaneous Hepatitis B vaccine delivered without NPs could induce humoral immunity without activating mucosal immunity, however when loaded in glycol-chitosan-NPs and delivered through intranasal pathway, both immune responses could be strongly stimulated [209]. Orally delivered vaccine is a convenient pathway capable of generating both mucosal and systemic immunity. But for oral vaccines to trigger strong and long lasting immune response they must overcome the problem of their breakdown in the GI tract and as well as their rapid clearance, which requires large multiple doses [210, 211]. Therefore, by employing oral vaccine coupled with NPs, such problems can be circumvented. For example bilosomes which are resistant to the enzymes of GI tract, when loaded with tetanus toxoid, resistant to the GI tract, could generate better immune responses through the oral route [212]. Intranasal administration is another comfortable route that requires fewer antigens as compared to oral route and also systemic responses is strongly stimulated. Although, complications like rapid removal and dosing having poor reproducibility are encountered using this route,49 which can be avoided by employing mucoadhesive NPs that induces augmented cell-mediated, systemic and mucosal immune response. Adopting this pathway, chitosan-PLGA NPs and AuNPs have been found sufficiently effective for human [213, 214] and veterinary use [215]. Skin being the largest organ, covering an area of\naround 20 square feet, contains a large number of immunocompetent cells capable of stimulating the responses of innate and adaptive immunity. Consequently, intradermally delivered vaccines are found to more efficient than those administered though subcutaneous or intramuscular pathway. As a result, skin represents the ideal pathway. But the complications associated include penetration of drug in optimized dose through the stratum corneum cannot be easily determined. However, NP's penetration capability can be estimated by its dimensions, composition as well as the hydric properties and also dictated by the physiological state of skin like whether it lesioned or healthy.49 In spite of innumerable advantages of NPs based vaccines over conventional ones, they still have certain flaws like release of drug prior to reaching the target. Also, any alteration or modulation of surface chemistry and structure of NPs may result in their uptake by non-targeted cells, thus leading undesirable effects. Besides, knowledge about pharmacokinetics of NPs based vaccine delivery systems and their cytotoxicity, which are to be delivered probably to the healthy population, is still inadequate. Therefore, even minor risk or adverse effects are not acceptable [208, 211].\nDeficiency of current research and future prospects\nNanomedicine has come a long way in its brief history but there are still some voids that have to be explored so as to enjoy the bountiful results. Nanoformulation of drugs, that appear to bring a turning point in the use of antibiotics are being extensively studied in multiple nanoplatforms but there are certain clinical limitations that have waned clinicians enthusiasm in the recent past, like the associated toxicity and obstructions in drug delivery.\nConditions inside the body cannot be emulated in-vitro therefore, until the study is not extended to in-vivo, it is of little significance. Beside antibacterial efficacy of NPs and of encapsulated drugs, others aspects like successful site specific drug delivery, delivery without leakage, cytotoxicity, premature drug release, removal by the phagocytic action of RES and stability in the conditions inside the body cannot be evaluated through in vitro studies.\nMajor deficiency of existing studies is that, unified standards cannot be established on the antibacterial mechanisms of NPs. Since bacterial activity varies with different NPs, as well as with the conditions of the medium. Moreover, different bacteria show variations in their behavior under the bactericidal effect of same NPs, which often make it difficult to estimate antibacterial activity of each NP. Disparity in the behavior of bacteria as well as the NPs make it mandatory to expand our studies by employing different bacteria as well as altering the conditions under which experiment is performed.\nMoreover our researches should not be confined to only susceptible bacterial strains to enumerate of NPs antibacterial action.\nRegarding the mechanism of antibacterial action of NPs, there are still many unanswered questions for example numerous studies ascribe ROS production as the main cause of their antibacterial activity, while for others it may not have any\nconnection with the bacterial metabolism and in some, antibacterial action is due to all three proposed mechanisms. Due to such uncertainties, mechanisms of antibacterial activity of NPs are worth emphasizing in future studies. Predominance of different mechanisms on changing the type of NP being used as well as under different conditions can be analyzed and quantified. Accordingly, such conditions can be established, that can potentiate the predominant mechanism of antibacterial activity in each case.\nBesides, in the sea of options brimming before us, it often becomes difficult to select a particular NP that suits best to our study. Therefore, comparative studies are always of paramount importance that help us to pick the most appropriate option. Comparative study under particular condition with specific strain to select the best NPs or by elucidating antibacterial activity of a particular NPs under different conditions, are needed to be performed. Moreover, drug loading efficiency or successful delivery of drug can be compared for different NPs, under different conditions and for different routes. Implementation of the information provided will probably help in designing NPs having biocompatibility, better efficiency, as well as clinical feasibility, and thereby contributing to the progress this field of nanomedicine."
    }, {
      "heading" : "Conclusion",
      "text" : "As the methods and techniques involved in NPs formulation constantly advances, various innovative strategies have arisen, further augmenting the NP's therapeutic efficacy against different infections. NPs appear to be one of the potential treatments for infectious illnesses by selectively targeting difficult-to reach locations, where pathogens generally reside. Moreover, along with improved efficacy of drugs, NPs optimize physicochemical characteristics, thus permitting the clinical applications of newly designed molecules and employing convenient pathways for their administration. Besides, it causes reduced dosages of drugs, fewer adverse effects, improved bioavailability and better administration schedules. On the other hand, they also have some limitations like knowledge about the toxic effects, metabolism, clearance of NPs and ideal targets of certain infections as well as their nature is still not adequate. These glitches along with the slow progress in reproducing preclinical studies to clinical trials have reduced the probability of developing efficacious NPs systems. Moreover, scarcity of funds, inefficient regulation as well as the poor cost–benefit balance also obstructs the progression in the direction of commercial marketing and their addition in the common therapeutic arsenal. Consequently, the number of preclinical systems that have gained regulatory approval is small. To ensure the actual success of nanomedicine, the best way requires interdisciplinary collaboration. Pharmacists, biologists, physicians etc. need to formulate more efficient therapeutic agents, physicists must seek to develop good quantitative techniques, translation of this knowledge to clinical trials, must be done by clinical researchers. Moreover, sufficient funding for the accessibility of these products in the market is also crucial. With such interdisciplinary approaches, it can be anticipated that nanotechnology will soon bring improvements in the treatment of bacterial infections."
    }, {
      "heading" : "Appendix A. Supplementary data",
      "text" : "Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.nano.2017.06.015."
    } ],
    "references" : [ {
      "title" : "Photoexcited quantum dots for killing multidrug-resistant bacteria",
      "author" : [ "CM Courtney", "SM Goodman", "JA McDaniel", "NE Madinger", "A Chatterjee", "P. Nagpal" ],
      "venue" : "Nat Mater",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2016
    }, {
      "title" : "Molecular mechanisms of antibacterial multidrug resistance",
      "author" : [ "Alekshun MN", "Levy SB" ],
      "venue" : "Cell",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2007
    }, {
      "title" : "Delivery systems to increase the selectivity of antibiotics in phagocytic cells",
      "author" : [ "E Briones", "CI Colino", "JM. Lanao" ],
      "venue" : "J Control Release",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2008
    }, {
      "title" : "Nanoparticulate delivery systems for antiviral drugs",
      "author" : [ "D Lembo", "R. Cavalli" ],
      "venue" : "Antivir Chem Chemother",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2010
    }, {
      "title" : "Preparation and optimization of Meropenem-loaded solid lipid nanoparticles: in vitro evaluation and molecular modeling. AAPS PharmSciTech 2016:1-15",
      "author" : [ "EK Mhango", "RS Kalhapure", "M Jadhav", "SJ Sonawane", "C Mocktar", "S Vepuri" ],
      "venue" : null,
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2016
    }, {
      "title" : "Nanomedicine: silence the target",
      "author" : [ "C. Plank" ],
      "venue" : "Nat Nanotechnol",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2009
    }, {
      "title" : "Nanoparticles vs. biofilms: a battle against another paradigm of antibiotic resistance",
      "author" : [ "Qayyum S", "Khan AU" ],
      "venue" : "Med Chem Commun",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2016
    }, {
      "title" : "Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome(R) or Fungizone",
      "author" : [ "JL Italia", "A Sharp", "KC Carter", "P Warn", "MN. Kumar" ],
      "venue" : "PLoS One 2011;6(10):e25744",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2011
    }, {
      "title" : "Highly stable, protein capped gold nanoparticles as effective drug delivery vehicles for amino-glycosidic antibiotics",
      "author" : [ "L Rastogi", "AJ Kora", "J. Arunachalam" ],
      "venue" : "Mater Sci Eng C",
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2012
    }, {
      "title" : "Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents",
      "author" : [ "AM Allahverdiyev", "KV Kon", "ES Abamor", "M Bagirova", "M. Rafailovich" ],
      "venue" : "Expert Rev Anti Infect Ther",
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2011
    }, {
      "title" : "Advances in nanomedicines for malaria treatment",
      "author" : [ "NP Aditya", "PG Vathsala", "V Vieira", "RS Murthy", "EB. Souto" ],
      "venue" : "Adv Colloid Interface Sci 2013;201:1-17",
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 2013
    }, {
      "title" : "Oxidative stress-mediated antibacterial activity of graphene oxide and reduced graphene oxide in Pseudomonas Aeruginosa",
      "author" : [ "S Gurunathan", "JW Han", "AA Dayem", "V Eppakayala", "JH. Kim" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2012
    }, {
      "title" : "Silver nanoparticles embedded in zeolite membranes release of silver ions and mechanism of antibacterial action",
      "author" : [ "A Nagy", "A Harrison", "S Sabbani", "RS Munson Jr.", "PK Dutta", "WJ. Waldman" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2011
    }, {
      "title" : "Mechanisms of antibacterial activity of MgO: non-ROS mediated toxicity of MgO nanoparticles towards Escherichia Coli",
      "author" : [ "YH Leung", "AM Ng", "X Xu", "Z Shen", "LA Gethings", "MT Wong" ],
      "venue" : null,
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2014
    }, {
      "title" : "Review on zinc oxide nanoparticles: antibacterial activity and toxicity mechanism",
      "author" : [ "A Sirelkhatim", "S Mahmud", "A Seeni", "NH Kaus", "LC Ann", "SK Bakhori" ],
      "venue" : null,
      "citeRegEx" : "15",
      "shortCiteRegEx" : "15",
      "year" : 2015
    }, {
      "title" : "Nanoparticle therapeutics: an emerging treatment modality for cancer",
      "author" : [ "ME Davis", "Z Chen", "DM. Shin" ],
      "venue" : "Nat Rev Drug Discov",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 2008
    }, {
      "title" : "Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery pharmacokinetic studies on rabbits",
      "author" : [ "P Chetoni", "S Burgalassi", "D Monti", "S Tampucci", "V Tullio", "AM Cuffini" ],
      "venue" : "Pharm Biopharm 2016;109:214-23",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2016
    }, {
      "title" : "Liposomes as nanomedical devices. Nanomedicine 2015;10:975",
      "author" : [ "G Bozzuto", "A. Molinari" ],
      "venue" : null,
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2015
    }, {
      "title" : "Liposome: classification, preparation, and applications",
      "author" : [ "A Akbarzadeh", "R Rezaei-Sadabady", "S Davaran", "SW Joo", "N Zarghami", "Y Hanifehpour" ],
      "venue" : "Nanoscale Res Lett 2013;8(1):102",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 2013
    }, {
      "title" : "Biodegradable polymeric nanoparticles based drug delivery systems",
      "author" : [ "A Kumari", "SK Yadav", "SC. Yadav" ],
      "venue" : "Biointerfaces",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2010
    }, {
      "title" : "Designing polymeric nanoparticles for targeted drug delivery system",
      "author" : [ "II Muhamad", "S Selvakumaran", "NAM. Lazim" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2014
    }, {
      "title" : "Progress of drug-loaded polymeric micelles into clinical studies",
      "author" : [ "H Cabral", "K. Kataoka" ],
      "venue" : "J Control Release",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2014
    }, {
      "title" : "Polymeric micelles in mucosal drug delivery: challenges towards clinical translation",
      "author" : [ "Sosnik A", "Raskin MM" ],
      "venue" : null,
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2015
    }, {
      "title" : "Recent advances in the design, development, and targeting mechanisms of polymeric micelles for delivery of siRNA in cancer therapy",
      "author" : [ "Amjad MW", "Kesharwani P", "Amin MCIM", "Iyer AK" ],
      "venue" : "Prog Polym Sci 2017;64:154-81",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2017
    }, {
      "title" : "UVS. Solid lipid nanoparticles-a review",
      "author" : [ "Yadav NEHA", "Khatak SUNIL", "Sara" ],
      "venue" : "Appl Pharm",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2013
    }, {
      "title" : "Iron oxide nanoparticles in modern microbiology and biotechnology",
      "author" : [ "R Dinali", "A Ebrahiminezhad", "M Manley-Harris", "Y Ghasemi", "A. Berenjian" ],
      "venue" : "Crit Rev Microbiol",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2017
    }, {
      "title" : "Iron oxide nanoparticles inhibit tumour growth by inducing proinflammatory macrophage polarization in tumour tissues",
      "author" : [ "S Zanganeh", "G Hutter", "R Spitler", "O Lenkov", "M Mahmoudi", "A Shaw" ],
      "venue" : "Nat Nanotechnol",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 2016
    }, {
      "title" : "Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer",
      "author" : [ "S Laurent", "M. Mahmoudi" ],
      "venue" : "Mol Epidemiol Genet",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2011
    }, {
      "title" : "Quantum dots—characterization, preparation and usage in biological systems",
      "author" : [ "J Drbohlavova", "V Adam", "R Kizek", "J. Hubalek" ],
      "venue" : "Mol Sci",
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 2009
    }, {
      "title" : "Gold nanoprobes for theranostics",
      "author" : [ "B Panchapakesan", "B Book-Newell", "P Sethu", "M Rao", "J. Irudayaraj" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2011
    }, {
      "title" : "Gold nanoparticles: optical properties and implementations in cancer diagnosis and photothermal therapy",
      "author" : [ "Huang X", "El-Sayed MA" ],
      "venue" : "J Adv Res",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2010
    }, {
      "title" : "Metal-based nanoparticles and their toxicity assessment",
      "author" : [ "AM Schrand", "MF Rahman", "SM Hussain", "JJ Schlager", "DA Smith", "AF. Syed" ],
      "venue" : "Wiley Interdiscip Rev Nanomed Nanobiotechnol",
      "citeRegEx" : "32",
      "shortCiteRegEx" : "32",
      "year" : 2010
    }, {
      "title" : "Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting",
      "author" : [ "Gupta U", "Jain NK" ],
      "venue" : "Adv Drug Deliv Rev 2010;62(4):478-90",
      "citeRegEx" : "33",
      "shortCiteRegEx" : "33",
      "year" : 2010
    }, {
      "title" : "Nanotoxicity: the toxicity research progress of metal and metalcontaining nanoparticles",
      "author" : [ "L Ding", "Z Liu", "M Okweesi Aggrey", "C Li", "J Chen", "L. Tong" ],
      "venue" : "Med Chem",
      "citeRegEx" : "34",
      "shortCiteRegEx" : "34",
      "year" : 2015
    }, {
      "title" : "Silver nanoparticles: synthesis, characterization, properties, applications, and therapeutic approaches",
      "author" : [ "XF Zhang", "ZG Liu", "W Shen", "S. Gurunathan" ],
      "venue" : "Mol Sci",
      "citeRegEx" : "35",
      "shortCiteRegEx" : "35",
      "year" : 2016
    }, {
      "title" : "Mesoporous silica nanoparticles in drug delivery and biomedical applications",
      "author" : [ "Y Wang", "Q Zhao", "N Han", "L Bai", "J Li", "J Liu" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 2015
    }, {
      "title" : "Mesoporous silica nanoparticles in target drug delivery system: a review",
      "author" : [ "C Bharti", "U Nagaich", "AK Pal", "N. Gulati" ],
      "venue" : "Pharm Investig",
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2015
    }, {
      "title" : "Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future",
      "author" : [ "RR Arvizo", "S Bhattacharyya", "RA Kudgus", "K Giri", "R Bhattacharya", "P. Mukherjee" ],
      "venue" : "Chem Soc Rev 2012;41(7):2943-70",
      "citeRegEx" : "38",
      "shortCiteRegEx" : "38",
      "year" : 2012
    }, {
      "title" : "Quantum dots in cell biology",
      "author" : [ "Barroso MM" ],
      "venue" : "J Histochem Cytochem",
      "citeRegEx" : "39",
      "shortCiteRegEx" : "39",
      "year" : 2011
    }, {
      "title" : "Quantum dots versus organic dyes as fluorescent labels",
      "author" : [ "U Resch-Genger", "M Grabolle", "S Cavaliere-Jaricot", "R Nitschke", "T. Nann" ],
      "venue" : "Nat Methods",
      "citeRegEx" : "40",
      "shortCiteRegEx" : "40",
      "year" : 2008
    }, {
      "title" : "an updated review of functionalized carbon nanotubes in electrochemical sensors",
      "author" : [ "C Gao", "Z Guo", "JH Liu", "nanotubes Huang XJ. The new age of carbon" ],
      "venue" : "Nanoscale 2012;4(6):1948-63.  2298  S. Zaidi et al / Nanomedicine: Nanotechnology, Biology, and Medicine 13",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Carbon nanotubes: properties, synthesis, purification, and medical applications",
      "author" : [ "A Eatemadi", "H Daraee", "H Karimkhanloo", "M Kouhi", "N Zarghami", "A Akbarzadeh" ],
      "venue" : "Nanoscale Res Lett 2014;9(1):393",
      "citeRegEx" : "42",
      "shortCiteRegEx" : "42",
      "year" : 2014
    }, {
      "title" : "Controlled nucleation for the regulation of particle size in monodisperse gold suspensions",
      "author" : [ "G. Frens" ],
      "venue" : "Nature",
      "citeRegEx" : "43",
      "shortCiteRegEx" : "43",
      "year" : 1973
    }, {
      "title" : "Oxygen and air nanobubble water solution promote the growth of plants, fishes, and mice",
      "author" : [ "K Ebina", "K Shi", "M Hirao", "J Hashimoto", "Y Kawato", "S Kaneshiro" ],
      "venue" : "PLoS One 2013;8(6):e65339",
      "citeRegEx" : "44",
      "shortCiteRegEx" : "44",
      "year" : 2013
    }, {
      "title" : "Nanosilver particles in medical applications: synthesis, performance, and toxicity",
      "author" : [ "L Ge", "Q Li", "M Wang", "J Ouyang", "X Li", "MM. Xing" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "45",
      "shortCiteRegEx" : "45",
      "year" : 2014
    }, {
      "title" : "Polymer-encapsulated organic nanoparticles for fluorescence and photoacoustic imaging",
      "author" : [ "K Li", "B. Liu" ],
      "venue" : "Chem Soc Rev",
      "citeRegEx" : "46",
      "shortCiteRegEx" : "46",
      "year" : 2014
    }, {
      "title" : "Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic",
      "author" : [ "A Puri", "K Loomis", "B Smith", "JH Lee", "A Yavlovich", "E Heldman" ],
      "venue" : "Crit Rev Ther Drug Carrier Syst",
      "citeRegEx" : "47",
      "shortCiteRegEx" : "47",
      "year" : 2009
    }, {
      "title" : "AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration",
      "author" : [ "Patel PA", "Patravale VB" ],
      "venue" : "J Biomed Nanotechnol",
      "citeRegEx" : "48",
      "shortCiteRegEx" : "48",
      "year" : 2011
    }, {
      "title" : "Liposomes as nanovaccine delivery systems",
      "author" : [ "KA Ghaffar", "AK Giddam", "M Zaman", "M Skwarczynski", "I. Toth" ],
      "venue" : "Curr Top Med Chem",
      "citeRegEx" : "49",
      "shortCiteRegEx" : "49",
      "year" : 2014
    }, {
      "title" : "The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices",
      "author" : [ "Jain RA" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "50",
      "shortCiteRegEx" : "50",
      "year" : 2000
    }, {
      "title" : "Glycyrrhizin conjugated chitosan nanoparticlesfor hepatocyte-targeted delivery of lamivudine",
      "author" : [ "D Mishra", "N Jain", "V Rajoriya", "AK. Jain" ],
      "venue" : "J Pharm Pharmacol",
      "citeRegEx" : "51",
      "shortCiteRegEx" : "51",
      "year" : 2014
    }, {
      "title" : "The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection",
      "author" : [ "IC Goncalves", "PC Henriques", "CL Seabra", "MC. Martins" ],
      "venue" : "Expert Rev Anti Infect Ther",
      "citeRegEx" : "52",
      "shortCiteRegEx" : "52",
      "year" : 2014
    }, {
      "title" : "Stimuli-responsive polymers and their applications in drug delivery",
      "author" : [ "P Bawa", "V Pillay", "YE Choonara", "LC. Du Toit" ],
      "venue" : "Biomed Mater",
      "citeRegEx" : "53",
      "shortCiteRegEx" : "53",
      "year" : 2009
    }, {
      "title" : "Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis",
      "author" : [ "M Kaur", "T Garg", "G Rath", "AK. Goyal" ],
      "venue" : "Crit Rev Ther Drug Carrier Syst",
      "citeRegEx" : "54",
      "shortCiteRegEx" : "54",
      "year" : 2014
    }, {
      "title" : "Current applications of nanoparticles in infectious diseases",
      "author" : [ "H Zazo", "IC Colino", "MJ. Lanao" ],
      "venue" : "J Control Release",
      "citeRegEx" : "55",
      "shortCiteRegEx" : "55",
      "year" : 2016
    }, {
      "title" : "Anti-HIV-1 nanotherapeutics: promises and challenges for the future",
      "author" : [ "SD Mahajan", "R Aalinkeel", "LawWC", "JL Reynolds", "BB Nair", "DE Sykes" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "56",
      "shortCiteRegEx" : "56",
      "year" : 2012
    }, {
      "title" : "Colloidal gold part I",
      "author" : [ "J. Turkevich" ],
      "venue" : "Gold Bull 1985;18(3):86-91",
      "citeRegEx" : "57",
      "shortCiteRegEx" : "57",
      "year" : 1985
    }, {
      "title" : "Introduction to metallic nanoparticles",
      "author" : [ "VV Mody", "R Siwale", "A Singh", "HR. Mody" ],
      "venue" : "J Pharm Bioallied Sci",
      "citeRegEx" : "59",
      "shortCiteRegEx" : "59",
      "year" : 2010
    }, {
      "title" : "Multiple strategies to activate gold nanoparticles as antibiotics",
      "author" : [ "Y Zhao", "X. Jiang" ],
      "venue" : "Nanoscale",
      "citeRegEx" : "60",
      "shortCiteRegEx" : "60",
      "year" : 2013
    }, {
      "title" : "Physiologically important metal nanoparticles and their toxicity",
      "author" : [ "J Sengupta", "S Ghosh", "P Datta", "A Gomes", "A. Gomes" ],
      "venue" : "J Nanosci Nanotechnol",
      "citeRegEx" : "61",
      "shortCiteRegEx" : "61",
      "year" : 2014
    }, {
      "title" : "Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications",
      "author" : [ "AK Gupta", "RR Naregalkar", "VD Vaidya", "M. Gupta" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "62",
      "shortCiteRegEx" : "62",
      "year" : 2007
    }, {
      "title" : "Biomedical applications of distally controlled magnetic nanoparticles",
      "author" : [ "JL Corchero", "A. Villaverde" ],
      "venue" : "Trends Biotechnol",
      "citeRegEx" : "63",
      "shortCiteRegEx" : "63",
      "year" : 2009
    }, {
      "title" : "Microfluidic applications of magnetic particles for biological analysis and catalysis",
      "author" : [ "MA Gijs", "F Lacharme", "U. Lehmann" ],
      "venue" : "Chem Rev 2009;110(3):1518-63",
      "citeRegEx" : "64",
      "shortCiteRegEx" : "64",
      "year" : 2009
    }, {
      "title" : "Microfluidic technologies for accelerating the clinical translation of nanoparticles",
      "author" : [ "PM Valencia", "OC Farokhzad", "R Karnik", "R. Langer" ],
      "venue" : "Nat Nanotechnol",
      "citeRegEx" : "65",
      "shortCiteRegEx" : "65",
      "year" : 2012
    }, {
      "title" : "A magneto-DNA nanoparticle system for rapid detection and phenotyping of bacteria",
      "author" : [ "HJ Chung", "CM Castro", "H Im", "H Lee", "R. Weissleder" ],
      "venue" : "Nat Nanotechnol",
      "citeRegEx" : "66",
      "shortCiteRegEx" : "66",
      "year" : 2013
    }, {
      "title" : "Selective in vitro photothermal nano-therapy of MRSA infections mediated by IgG conjugated gold nanoparticles",
      "author" : [ "L Mocan", "C Matea", "FA Tabaran", "O Mosteanu", "T Pop", "C Puia" ],
      "venue" : null,
      "citeRegEx" : "67",
      "shortCiteRegEx" : "67",
      "year" : 2016
    }, {
      "title" : "Gold nanoparticles enhance methylene blue-induced photodynamic therapy: a novel therapeutic approach to inhibit Candida Albicans biofilm",
      "author" : [ "S Khan", "F Alam", "A Azam", "AU. Khan" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "68",
      "shortCiteRegEx" : "68",
      "year" : 2012
    }, {
      "title" : "Enhancing nanoparticle-based visible detection by controlling the extent of aggregation",
      "author" : [ "S Lim", "OK Koo", "YS You", "YE Lee", "MS Kim", "PS Chang" ],
      "venue" : null,
      "citeRegEx" : "69",
      "shortCiteRegEx" : "69",
      "year" : 2012
    }, {
      "title" : "Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria",
      "author" : [ "MK Rai", "SD Deshmukh", "AP Ingle", "AK. Gade" ],
      "venue" : "J Appl Microbiol",
      "citeRegEx" : "70",
      "shortCiteRegEx" : "70",
      "year" : 2012
    }, {
      "title" : "Biofabrication of broad range antibacterial and antibiofilm silver nanoparticles",
      "author" : [ "Qayyum S", "Khan AU" ],
      "venue" : "IET Nanobiotechnol",
      "citeRegEx" : "71",
      "shortCiteRegEx" : "71",
      "year" : 2016
    }, {
      "title" : "Antibiofilm efficacy of green synthesized graphene oxide-silver nanocomposite using Lagerstroemia Speciosa floral extract: a comparative study on inhibition of gram-positive and gram-negative biofilms",
      "author" : [ "S Kulshrestha", "S Qayyum", "AU. Khan" ],
      "venue" : "Microb Pathog 2017;103:167-77",
      "citeRegEx" : "72",
      "shortCiteRegEx" : "72",
      "year" : 2017
    }, {
      "title" : "Antibiofilm action of a toluidine blue O-silver nanoparticle conjugate on Streptococcus Mutans: a mechanism of type I photodynamic therapy",
      "author" : [ "L Misba", "S Kulshrestha", "AU. Khan" ],
      "venue" : "Biofouling",
      "citeRegEx" : "73",
      "shortCiteRegEx" : "73",
      "year" : 2016
    }, {
      "title" : "Production of silver nanoparticles with strong and stable antimicrobial activity against highly pathogenic and multidrug resistant bacteria",
      "author" : [ "A Saeb", "AS Alshammari", "H Al-Brahim", "KA. Al-Rubeaan" ],
      "venue" : "Sci World J 2014;2014",
      "citeRegEx" : "74",
      "shortCiteRegEx" : "74",
      "year" : 2014
    }, {
      "title" : "Nanomedicine (s) under the microscope",
      "author" : [ "R Duncan", "R. Gaspar" ],
      "venue" : "Mol Pharm",
      "citeRegEx" : "75",
      "shortCiteRegEx" : "75",
      "year" : 2011
    }, {
      "title" : "Quantum dot probes for bacteria distinguish escherichia coli mutants and permit in vivo imaging",
      "author" : [ "WM Leevy", "TN Lambert", "JR Johnson", "J Morris", "BD. Smith" ],
      "venue" : "Chem Commun",
      "citeRegEx" : "76",
      "shortCiteRegEx" : "76",
      "year" : 2008
    }, {
      "title" : "Encapsulation of zinc-rifampicin complex into transferrin-conjugated silver quantum-dots improves its antimycobacterial activity and stability and facilitates drug delivery into macrophages",
      "author" : [ "R Pati", "R Sahu", "J Panda", "A. Sonawane" ],
      "venue" : null,
      "citeRegEx" : "77",
      "shortCiteRegEx" : "77",
      "year" : 2016
    }, {
      "title" : "A graphene/ zinc oxide nanocomposite film protects dental implant surfaces against cariogenic Streptococcus mutans",
      "author" : [ "S Kulshrestha", "S Khan", "R Meena", "BR Singh", "AU. Khan" ],
      "venue" : "Biofouling",
      "citeRegEx" : "78",
      "shortCiteRegEx" : "78",
      "year" : 2014
    }, {
      "title" : "Synthesis, characterization, and antimicrobial properties of copper nanoparticles",
      "author" : [ "M. Sani Usman" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "79",
      "shortCiteRegEx" : "79",
      "year" : 2013
    }, {
      "title" : "Calcium fluoride nanoparticles induced suppression of Streptococcus Mutans biofilm: an in vitro and in vivo approach",
      "author" : [ "S Kulshrestha", "S Khan", "S Hasan", "ME Khan", "L Misba", "AU. Khan" ],
      "venue" : "Appl Microbiol Biotechnol",
      "citeRegEx" : "80",
      "shortCiteRegEx" : "80",
      "year" : 2016
    }, {
      "title" : "Antimicrobial activity of carbon-based nanoparticles",
      "author" : [ "S Maleki Dizaj", "A Mennati", "S Jafari", "K Khezri", "K. Adibkia" ],
      "venue" : null,
      "citeRegEx" : "81",
      "shortCiteRegEx" : "81",
      "year" : 2015
    }, {
      "title" : "Macrophages targeting of amphotericin B through mannosylated multiwalled carbon nanotubes",
      "author" : [ "J Pruthi", "NK Mehra", "NK. Jain" ],
      "venue" : "J Drug Target",
      "citeRegEx" : "82",
      "shortCiteRegEx" : "82",
      "year" : 2012
    }, {
      "title" : "Density functional and molecular docking studies towards investigating the role of single-wall carbon nanotubes as nanocarrier for loading and delivery of pyrazinamide antitubercular drug onto pncA protein",
      "author" : [ "N Saikia", "S Rajkhowa", "RC. Deka" ],
      "venue" : "J Comput Aided Mol Des 2013;27(3):257-76",
      "citeRegEx" : "83",
      "shortCiteRegEx" : "83",
      "year" : 2013
    }, {
      "title" : "Micro-and nanobubbles: a versatile non-viral platform for gene delivery",
      "author" : [ "R Cavalli", "A Bisazza", "D. Lembo" ],
      "venue" : null,
      "citeRegEx" : "84",
      "shortCiteRegEx" : "84",
      "year" : 2013
    }, {
      "title" : "present situation and prospects for the future",
      "author" : [ "L Wang", "C Hu", "nanoparticles Shao L. The antimicrobial activity of" ],
      "venue" : "Nanomedicine 2017;12:1227.  2299  S. Zaidi et al / Nanomedicine: Nanotechnology, Biology, and Medicine 13",
      "citeRegEx" : "85",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Antibioticloaded, silver core-embedded mesoporous silica nanovehicles as a synergistic antibacterial agent for the treatment of drug-resistant infections",
      "author" : [ "Y Wang", "X Ding", "Y Chen", "M Guo", "Y Zhang", "X Guo" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "86",
      "shortCiteRegEx" : "86",
      "year" : 2016
    }, {
      "title" : "Eradication of multi-drug resistant bacteria by a novel Zn-doped CuO nanocomposite",
      "author" : [ "E Malka", "I Perelshtein", "A Lipovsky", "Y Shalom", "L Naparstek", "N Perkas" ],
      "venue" : null,
      "citeRegEx" : "87",
      "shortCiteRegEx" : "87",
      "year" : 2013
    }, {
      "title" : "Cu-doped TiO 2 nanoparticles enhance survival of Shewanella oneidensis MR-1 under ultraviolet light (UV) exposure",
      "author" : [ "B Wu", "WQ Zhuang", "M Sahu", "P Biswas", "YJ. Tang" ],
      "venue" : "Sci Total Environ",
      "citeRegEx" : "88",
      "shortCiteRegEx" : "88",
      "year" : 2011
    }, {
      "title" : "Synthesis, characterization, antimicrobial activity and mechanism of a novel hydroxyapatite whisker/nano zinc oxide biomaterial",
      "author" : [ "J Yu", "W Zhang", "Y Li", "G Wang", "L Yang", "J Jin" ],
      "venue" : "Biomed Mater",
      "citeRegEx" : "89",
      "shortCiteRegEx" : "89",
      "year" : 2014
    }, {
      "title" : "Antibacterial activity of silver nanoparticles: sensitivity of different salmonella serovars",
      "author" : [ "C Losasso", "S Belluco", "V Cibin", "P Zavagnin", "I Mičetić", "F Gallocchio" ],
      "venue" : "Front Microbiol",
      "citeRegEx" : "90",
      "shortCiteRegEx" : "90",
      "year" : 2014
    }, {
      "title" : "Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency",
      "author" : [ "A Lesniak", "A Salvati", "MJ Santos-Martinez", "MW Radomski", "KA Dawson", "C. Åberg" ],
      "venue" : "J Am Chem Soc 2013;135:1438-44",
      "citeRegEx" : "91",
      "shortCiteRegEx" : "91",
      "year" : 2013
    }, {
      "title" : "Regioselective sequential modification of chitosan via Azide-alkyne click reaction: synthesis, characterization, and antimicrobial activity of chitosan derivatives and nanoparticles",
      "author" : [ "A Sarwar", "H Katas", "SN Samsudin", "NM. Zin" ],
      "venue" : "PLoS One 2015;10(4):e0123084",
      "citeRegEx" : "92",
      "shortCiteRegEx" : "92",
      "year" : 2015
    }, {
      "title" : "Photocatalytic antibacterial activity of nano-TiO 2 (anatase)based thin films: effects on Escherichia Coli cells and fatty acids",
      "author" : [ "U Joost", "K Juganson", "M Visnapuu", "M Mortimer", "A Kahru", "E Nõmmiste" ],
      "venue" : null,
      "citeRegEx" : "93",
      "shortCiteRegEx" : "93",
      "year" : 2015
    }, {
      "title" : "Evidence for compression of Escherichia Coli K12 cells under the effect of TiO2 nanoparticles",
      "author" : [ "Zhukova LV" ],
      "venue" : "ACS Appl Mater Interfaces",
      "citeRegEx" : "94",
      "shortCiteRegEx" : "94",
      "year" : 2015
    }, {
      "title" : "Alteration of intracellular protein expressions as a key mechanism of the deterioration of bacterial denitrification caused by copper oxide nanoparticles",
      "author" : [ "Y Su", "X Zheng", "Y Chen", "M Li", "K. Liu" ],
      "venue" : null,
      "citeRegEx" : "95",
      "shortCiteRegEx" : "95",
      "year" : 2015
    }, {
      "title" : "Strategies in the design of nanoparticles for therapeutic applications",
      "author" : [ "Petros RA", "DeSimone JM" ],
      "venue" : "Nat Rev Drug Discov",
      "citeRegEx" : "96",
      "shortCiteRegEx" : "96",
      "year" : 2010
    }, {
      "title" : "Long-circulating and targetspecific nanoparticles: theory to practice",
      "author" : [ "SM Moghimi", "AC Hunter", "JC. Murray" ],
      "venue" : "Pharmacol Rev 2001;53(2):283-318",
      "citeRegEx" : "97",
      "shortCiteRegEx" : "97",
      "year" : 2001
    }, {
      "title" : "Immunological properties of engineered nanomaterials",
      "author" : [ "Dobrovolskaia MA", "McNeil SE" ],
      "venue" : "Nat Nanotechnol",
      "citeRegEx" : "98",
      "shortCiteRegEx" : "98",
      "year" : 2007
    }, {
      "title" : "Mitotic trafficking of silicon microparticles",
      "author" : [ "RE Serda", "S Ferrati", "B Godin", "E Tasciotti", "X Liu", "M. Ferrari" ],
      "venue" : "Nanoscale",
      "citeRegEx" : "99",
      "shortCiteRegEx" : "99",
      "year" : 2009
    }, {
      "title" : "Trubetskoy VS.Which polymers can make nanoparticulate drug carriers long-circulating",
      "author" : [ "VP Torchilin" ],
      "venue" : "Adv Drug Deliv Rev",
      "citeRegEx" : "100",
      "shortCiteRegEx" : "100",
      "year" : 1995
    }, {
      "title" : "Amphiphilic block copolymers for drug delivery",
      "author" : [ "ML Adams", "A Lavasanifar", "GS. Kwon" ],
      "venue" : "J Pharm Sci",
      "citeRegEx" : "101",
      "shortCiteRegEx" : "101",
      "year" : 2003
    }, {
      "title" : "Role of target geometry in phagocytosis",
      "author" : [ "JA Champion", "S. Mitragotri" ],
      "venue" : "S A",
      "citeRegEx" : "102",
      "shortCiteRegEx" : "102",
      "year" : 2006
    }, {
      "title" : "Shape effects of filaments versus spherical particles in flow and drug delivery",
      "author" : [ "YAN Geng", "P Dalhaimer", "S Cai", "R Tsai", "M Tewari", "T Minko" ],
      "venue" : "Nat Nanotechnol",
      "citeRegEx" : "103",
      "shortCiteRegEx" : "103",
      "year" : 2007
    }, {
      "title" : "Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential",
      "author" : [ "S Patil", "A Sandberg", "E Heckert", "W Self", "S. Seal" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "104",
      "shortCiteRegEx" : "104",
      "year" : 2007
    }, {
      "title" : "Effect of nanoparticle concentration on zeta-potential measurement results and reproducibility",
      "author" : [ "R Tantra", "P Schulze", "P. Quincey" ],
      "venue" : "Particuology",
      "citeRegEx" : "105",
      "shortCiteRegEx" : "105",
      "year" : 2010
    }, {
      "title" : "Nanoparticle diffusion within intestinal mucus: threedimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles",
      "author" : [ "M Abdulkarim", "N Agulló", "B Cattoz", "P Griffiths", "A Bernkop-Schnürch", "SG Borros" ],
      "venue" : "Pharm Biopharm 2015;97:230-8",
      "citeRegEx" : "106",
      "shortCiteRegEx" : "106",
      "year" : 2015
    }, {
      "title" : "Therapeutic potential of nanoparticulate systems for macrophage targeting",
      "author" : [ "F Chellat", "Y Merhi", "A Moreau", "LH. Yahia" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "107",
      "shortCiteRegEx" : "107",
      "year" : 2005
    }, {
      "title" : "Vancomycin-modified mesoporous silica nanoparticles for selective recognition and killing of pathogenic grampositive bacteria over macrophage-like cells",
      "author" : [ "G Qi", "L Li", "F Yu", "H. Wang" ],
      "venue" : "ACS Appl Mater Interfaces",
      "citeRegEx" : "109",
      "shortCiteRegEx" : "109",
      "year" : 2013
    }, {
      "title" : "Nanoparticle approaches against bacterial infections.Wiley",
      "author" : [ "W Gao", "S Thamphiwatana", "P Angsantikul", "L. Zhang" ],
      "venue" : "Interdiscip Rev Nanomed Nanobiotechnol",
      "citeRegEx" : "110",
      "shortCiteRegEx" : "110",
      "year" : 2014
    }, {
      "title" : "Opening the flood-gates: how neutrophilendothelial interactions regulate permeability",
      "author" : [ "MR DiStasi", "K. Ley" ],
      "venue" : "Trends Immunol",
      "citeRegEx" : "111",
      "shortCiteRegEx" : "111",
      "year" : 2009
    }, {
      "title" : "The enhanced permeability retention effect: a new paradigm for drug targeting in infection",
      "author" : [ "EA Azzopardi", "EL Ferguson", "DW. Thomas" ],
      "venue" : "J Antimicrob Chemother",
      "citeRegEx" : "112",
      "shortCiteRegEx" : "112",
      "year" : 2013
    }, {
      "title" : "Adhesion of PLGA or Eudragit®/PLGA nanoparticles to staphylococcus and pseudomonas",
      "author" : [ "K Dillen", "C Bridts", "P Van der Veken", "P Cos", "J Vandervoort", "K Augustyns" ],
      "venue" : null,
      "citeRegEx" : "113",
      "shortCiteRegEx" : "113",
      "year" : 2008
    }, {
      "title" : "Antibacterial and hemolytic activities of pyridinium polymers as a function of the spatial relationship between the positive charge and the pendant alkyl tail",
      "author" : [ "V Sambhy", "BR Peterson", "A. Sen" ],
      "venue" : "Angew Chem Int Ed",
      "citeRegEx" : "114",
      "shortCiteRegEx" : "114",
      "year" : 2008
    }, {
      "title" : "Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs",
      "author" : [ "S Gunaseelan", "K Gunaseelan", "M Deshmukh", "X Zhang", "PJ. Sinko" ],
      "venue" : "Adv Drug Deliv Rev 2010;62(4):518-31",
      "citeRegEx" : "115",
      "shortCiteRegEx" : "115",
      "year" : 2010
    }, {
      "title" : "Active targeting schemes for nanoparticle systems in cancer therapeutics",
      "author" : [ "JD Byrne", "T Betancourt", "L. Brannon-Peppas" ],
      "venue" : "Adv Drug Deliv Rev 2008;60(15):1615-26",
      "citeRegEx" : "116",
      "shortCiteRegEx" : "116",
      "year" : 2008
    }, {
      "title" : "Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules",
      "author" : [ "SM Farkhani", "A Valizadeh", "H Karami", "S Mohammadi", "N Sohrabi", "F. Badrzadeh" ],
      "venue" : "Peptides",
      "citeRegEx" : "117",
      "shortCiteRegEx" : "117",
      "year" : 2014
    }, {
      "title" : "Antimicrobial and cell-penetrating properties of penetratin analogs: effect of sequence and secondary structure",
      "author" : [ "JS Bahnsen", "H Franzyk", "A Sandberg-Schaal", "HM. Nielsen" ],
      "venue" : "Biochim Biophys Acta",
      "citeRegEx" : "118",
      "shortCiteRegEx" : "118",
      "year" : 2013
    }, {
      "title" : "Vancomycin-modified nanoparticles for efficient targeting and preconcentration of gram-positive and gram-negative bacteria",
      "author" : [ "AJ Kell", "G Stewart", "S Ryan", "R Peytavi", "M Boissinot", "A Huletsky" ],
      "venue" : "ACS Nano 2008;2(9):1777-88",
      "citeRegEx" : "119",
      "shortCiteRegEx" : "119",
      "year" : 2008
    }, {
      "title" : "Solanum Tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations",
      "author" : [ "J Chen", "C Zhang", "Q Liu", "X Shao", "C Feng", "Y Shen" ],
      "venue" : "J Drug Target",
      "citeRegEx" : "120",
      "shortCiteRegEx" : "120",
      "year" : 2012
    }, {
      "title" : "Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of helicobacter pylori",
      "author" : [ "Umamaheshwari RB", "Jain NK" ],
      "venue" : "J Drug Target",
      "citeRegEx" : "121",
      "shortCiteRegEx" : "121",
      "year" : 2003
    }, {
      "title" : "Single-domain antibody-conjugated nanoaggregate-embedded beads for targeted detection of pathogenic bacteria",
      "author" : [ "PJ Huang", "LL Tay", "J Tanha", "S Ryan", "LK. Chau" ],
      "venue" : null,
      "citeRegEx" : "122",
      "shortCiteRegEx" : "122",
      "year" : 2009
    }, {
      "title" : "Silica encapsulated SERS nanoprobe conjugated to the bacteriophage tailspike protein for targeted detection of salmonella",
      "author" : [ "LL Tay", "PJ Huang", "J Tanha", "S Ryan", "X Wu", "J Hulse" ],
      "venue" : "Chem Commun",
      "citeRegEx" : "123",
      "shortCiteRegEx" : "123",
      "year" : 2012
    }, {
      "title" : "Glycosylation-mediated targeting of carriers",
      "author" : [ "S Kawakami", "M. Hashida" ],
      "venue" : "J Control Release",
      "citeRegEx" : "124",
      "shortCiteRegEx" : "124",
      "year" : 2014
    }, {
      "title" : "Drug delivery to the central nervous system by polymeric nanoparticles: what do we know",
      "author" : [ "J. Kreuter" ],
      "venue" : "Adv Drug Deliv Rev  2014;71:2-14",
      "citeRegEx" : "125",
      "shortCiteRegEx" : "125",
      "year" : 2014
    }, {
      "title" : "Targeting delivery of saquinavir to the brain using 8314 monoclonal antibody-grafted solid lipid nanoparticles",
      "author" : [ "Kuo YC", "Ko HF" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "126",
      "shortCiteRegEx" : "126",
      "year" : 2013
    }, {
      "title" : "Body distribution of azidothymidine bound to hexyl-cyanoacrylate  2300  S",
      "author" : [ "R Lobenberg", "L Araujo", "H Von Briesen", "E Rodgers", "J. Kreuter" ],
      "venue" : "Zaidi et al / Nanomedicine: Nanotechnology, Biology, and Medicine",
      "citeRegEx" : "127",
      "shortCiteRegEx" : "127",
      "year" : 2017
    }, {
      "title" : "Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice",
      "author" : [ "N Xu", "J Gu", "Y Zhu", "H Wen", "Q Ren", "J. Chen" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "128",
      "shortCiteRegEx" : "128",
      "year" : 2011
    }, {
      "title" : "Bacterial subversion of host innate immune pathways",
      "author" : [ "LA Baxt", "AC Garza-Mayers", "MB. Goldberg" ],
      "venue" : "Science",
      "citeRegEx" : "129",
      "shortCiteRegEx" : "129",
      "year" : 2013
    }, {
      "title" : "Microscopic localization of PEG-liposomes in a rat model of focal infection",
      "author" : [ "P Laverman", "ETM Dams", "G Storm", "TG Hafmans", "HJ Croes", "WJ Oyen" ],
      "venue" : "J Control Release",
      "citeRegEx" : "130",
      "shortCiteRegEx" : "130",
      "year" : 2001
    }, {
      "title" : "MR imaging with Ultrasmall superparamagnetic iron oxide particles in experimental soft-tissue infections in rats",
      "author" : [ "AH Kaim", "T Wischer", "T O'Reilly", "G Jundt", "J Fröhlich", "GK von Schulthess" ],
      "venue" : "Radiology",
      "citeRegEx" : "131",
      "shortCiteRegEx" : "131",
      "year" : 2002
    }, {
      "title" : "Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy 1994;40(4):256-64",
      "author" : [ "RT Mehta", "TJ McQueen", "A Keyhani", "G. López-Berestein" ],
      "venue" : null,
      "citeRegEx" : "132",
      "shortCiteRegEx" : "132",
      "year" : 1994
    }, {
      "title" : "Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages",
      "author" : [ "SP Vyas", "ME Kannan", "S Jain", "V Mishra", "P. Singh" ],
      "venue" : null,
      "citeRegEx" : "133",
      "shortCiteRegEx" : "133",
      "year" : 2004
    }, {
      "title" : "Bacteriaresponsive multifunctional nanogel for targeted antibiotic delivery",
      "author" : [ "MH Xiong", "YJ Li", "Y Bao", "XZ Yang", "B Hu", "J. Wang" ],
      "venue" : "Adv Mater",
      "citeRegEx" : "134",
      "shortCiteRegEx" : "134",
      "year" : 2012
    }, {
      "title" : "Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent mycobacterium tuberculosis",
      "author" : [ "F Chen", "J Zhou", "F Luo", "AB Mohammed", "XL. Zhang" ],
      "venue" : "Biochem Biophys Res Commun",
      "citeRegEx" : "135",
      "shortCiteRegEx" : "135",
      "year" : 2007
    }, {
      "title" : "Selection and characterization of aptamers against salmonella typhimurium using whole-bacterium systemic evolution of ligands by exponential enrichment (SELEX)",
      "author" : [ "N Duan", "S Wu", "X Chen", "Y Huang", "Y Xia", "X Ma" ],
      "venue" : "J Agric Food Chem",
      "citeRegEx" : "136",
      "shortCiteRegEx" : "136",
      "year" : 2013
    }, {
      "title" : "pH-responsive nanoparticles for drug delivery",
      "author" : [ "W Gao", "J Chan", "OC. Farokhzad" ],
      "venue" : "Mol Pharm",
      "citeRegEx" : "137",
      "shortCiteRegEx" : "137",
      "year" : 2010
    }, {
      "title" : "pH-responsive release of chlorhexidine from modified nanoporous silica nanoparticles for dental applications",
      "author" : [ "H Fullriede", "P Abendroth", "N Ehlert", "K Doll", "J Schäske", "A Winkel" ],
      "venue" : "BioNanoMaterials",
      "citeRegEx" : "138",
      "shortCiteRegEx" : "138",
      "year" : 2016
    }, {
      "title" : "How to stabilize phospholipid liposomes (using nanoparticles)",
      "author" : [ "L Zhang", "S. Granick" ],
      "venue" : "Nano Lett 2006;6(4):694-8",
      "citeRegEx" : "139",
      "shortCiteRegEx" : "139",
      "year" : 2006
    }, {
      "title" : "Nanoparticle-assisted surface immobilization of phospholipid liposomes",
      "author" : [ "L Zhang", "L Hong", "Y Yu", "SC Bae", "S. Granick" ],
      "venue" : "J Am Chem Soc 2006;128(28):9026-7",
      "citeRegEx" : "140",
      "shortCiteRegEx" : "140",
      "year" : 2006
    }, {
      "title" : "On the formulation of pH-sensitive liposomes with long circulation times",
      "author" : [ "S Simões", "JN Moreira", "C Fonseca", "N Düzgüneş", "MCP. de Lima" ],
      "venue" : "Adv Drug Deliv Rev 2004;56(7):947-65",
      "citeRegEx" : "141",
      "shortCiteRegEx" : "141",
      "year" : 2004
    }, {
      "title" : "Stimuli-responsive liposome fusion mediated by gold nanoparticles",
      "author" : [ "D Pornpattananangkul", "S Olson", "S Aryal", "M Sartor", "CM Huang", "K Vecchio" ],
      "venue" : "ACS Nano 2010;4(4):1935",
      "citeRegEx" : "142",
      "shortCiteRegEx" : "142",
      "year" : 1935
    }, {
      "title" : "Hydrogel containing nanoparticle-stabilized liposomes for topical antimicrobial delivery",
      "author" : [ "W Gao", "D Vecchio", "J Li", "J Zhu", "Q Zhang", "V Fu" ],
      "venue" : "ACS Nano 2014;8(3):2900-7",
      "citeRegEx" : "143",
      "shortCiteRegEx" : "143",
      "year" : 2014
    }, {
      "title" : "Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics",
      "author" : [ "AF Radovic-Moreno", "TK Lu", "VA Puscasu", "CJ Yoon", "R Langer", "OC. Farokhzad" ],
      "venue" : "ACS Nano 2012;6(5):4279",
      "citeRegEx" : "144",
      "shortCiteRegEx" : "144",
      "year" : 2012
    }, {
      "title" : "Lipasesensitive polymeric triple-layered nanogel for “on-demand” drug delivery",
      "author" : [ "MH Xiong", "Y Bao", "XZ Yang", "YC Wang", "B Sun", "J. Wang" ],
      "venue" : "J Am Chem Soc 2012;134(9):4355-62",
      "citeRegEx" : "145",
      "shortCiteRegEx" : "145",
      "year" : 2012
    }, {
      "title" : "Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-helicobacter pylori therapy",
      "author" : [ "YH Lin", "CH Chang", "YS Wu", "YM Hsu", "SF Chiou", "YJ. Chen" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "146",
      "shortCiteRegEx" : "146",
      "year" : 2009
    }, {
      "title" : "Clearance Properties of Nano-Sized Particles and Molecules as Imaging Agents: Considerations and Caveats; 2008703-17",
      "author" : [ "M Longmire", "PL Choyke", "H. Kobayashi" ],
      "venue" : null,
      "citeRegEx" : "147",
      "shortCiteRegEx" : "147",
      "year" : 2008
    }, {
      "title" : "Renal clearance of quantum dots",
      "author" : [ "HS Choi", "W Liu", "P Misra", "E Tanaka", "JP Zimmer", "BI Ipe" ],
      "venue" : "Nat Biotechnol",
      "citeRegEx" : "148",
      "shortCiteRegEx" : "148",
      "year" : 2007
    }, {
      "title" : "Structural determinants of glomerular permeability",
      "author" : [ "WM Deen", "MJ Lazzara", "BD. Myers" ],
      "venue" : "Physiol 2001;281(4):F579-96",
      "citeRegEx" : "149",
      "shortCiteRegEx" : "149",
      "year" : 2001
    }, {
      "title" : "Hepatology, Principles and Practice: History, Morphology, Biochemistry, Diagnostics, Clinic, Therapy",
      "author" : [ "Kuntz E", "Kuntz HD" ],
      "venue" : null,
      "citeRegEx" : "150",
      "shortCiteRegEx" : "150",
      "year" : 2006
    }, {
      "title" : "Surface chemistry of gold nanoparticles mediates their exocytosis in macrophages",
      "author" : [ "Oh N", "Park JH" ],
      "venue" : "ACS Nano 2014;8(6):6232-41",
      "citeRegEx" : "151",
      "shortCiteRegEx" : "151",
      "year" : 2014
    }, {
      "title" : "Inhaled liposomal ciprofloxacin protects against a lethal infection in a murine model of pneumonic plague",
      "author" : [ "KA Hamblin", "SJ Armstrong", "KB Barnes", "C Davies", "T Laws", "JD Blanchard" ],
      "venue" : "Front Microbiol",
      "citeRegEx" : "152",
      "shortCiteRegEx" : "152",
      "year" : 2017
    }, {
      "title" : "Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections",
      "author" : [ "A Castoldi", "C Herr", "J Niederstraßer", "HI Labouta", "A Melero", "S Gordon" ],
      "venue" : "Pharm Biopharm",
      "citeRegEx" : "153",
      "shortCiteRegEx" : "153",
      "year" : 2016
    }, {
      "title" : "Novel antimicrobial peptide–modified azithromycin-loaded liposomes against methicillinresistant Staphylococcus Aureus",
      "author" : [ "X Liu", "Z Li", "WangX", "Y Chen", "F Wu", "MenK" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "154",
      "shortCiteRegEx" : "154",
      "year" : 2016
    }, {
      "title" : "Polymeric micellar nanoplatforms for Fenton reaction as a new class of antibacterial agents",
      "author" : [ "SC Park", "NH Kim", "W Yang", "JW Nah", "MK Jang", "D. Lee" ],
      "venue" : "J Control Release",
      "citeRegEx" : "155",
      "shortCiteRegEx" : "155",
      "year" : 2016
    }, {
      "title" : "Surface-adaptive, antimicrobially loaded, micellar nanocarriers with enhanced penetration and killing efficiency in staphylococcal biofilms",
      "author" : [ "Y Liu", "HJ Busscher", "B Zhao", "Y Li", "Z Zhang", "HC van der Mei" ],
      "venue" : "ACS Nano 2016;10(4):4779-89",
      "citeRegEx" : "156",
      "shortCiteRegEx" : "156",
      "year" : 2016
    }, {
      "title" : "Enhanced intracellular delivery and antibacterial efficacy of enrofloxacin-loaded docosanoic acid solid lipid nanoparticles against intracellular salmonella",
      "author" : [ "S Xie", "F Yang", "Y Tao", "D Chen", "W Qu", "L Huang" ],
      "venue" : null,
      "citeRegEx" : "157",
      "shortCiteRegEx" : "157",
      "year" : 2017
    }, {
      "title" : "Nanoparticles as tool for enhanced ophthalmic delivery of vancomycin: a multidistrict-based microbiological study, solid lipid nanoparticles formulation and evaluation",
      "author" : [ "C Yousry", "RH Fahmy", "T Essam", "HM El-Laithy", "SA. Elkheshen" ],
      "venue" : "Drug Dev Ind Pharm",
      "citeRegEx" : "158",
      "shortCiteRegEx" : "158",
      "year" : 2016
    }, {
      "title" : "Antibacterial efficacy of rifampin loaded solid lipid nanoparticles against Staphylococcus Epidermidis biofilm",
      "author" : [ "BSF Bazzaz", "B Khameneh", "H Zarei", "S. Golmohammadzadeh" ],
      "venue" : "Microb Pathog 2016;93:137-44",
      "citeRegEx" : "159",
      "shortCiteRegEx" : "159",
      "year" : 2016
    }, {
      "title" : "Superparamagnetic iron oxide-encapsulating polymersome nanocarriers for biofilm eradication",
      "author" : [ "BM Geilich", "I Gelfat", "S Sridhar", "AL van de Ven", "TJ. Webster" ],
      "venue" : "Biomaterials",
      "citeRegEx" : "160",
      "shortCiteRegEx" : "160",
      "year" : 2017
    }, {
      "title" : "Core–shell magnetic nanoparticles display synergistic antibacterial effects against Pseudomonas Aeruginosa and Staphylococcus Aureus when combined with cathelicidin ll-37 or selected ceragenins",
      "author" : [ "K Niemirowicz", "E Piktel", "AZ Wilczewska", "KH Markiewicz", "B Durnaś", "M Wątek" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "161",
      "shortCiteRegEx" : "161",
      "year" : 2016
    }, {
      "title" : "Reduced Staphylococcus Aureus biofilm formation in the presence of chitosan-coated iron oxide nanoparticles",
      "author" : [ "SF Shi", "JF Jia", "XK Guo", "YP Zhao", "DS Chen", "YY Guo" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "162",
      "shortCiteRegEx" : "162",
      "year" : 2016
    }, {
      "title" : "Gold-nanoparticles coated with the antimicrobial peptide esculentin-1a (1-21) NH 2 as a reliable strategy for antipseudomonal drugs",
      "author" : [ "B Casciaro", "M Moros", "S Rivera-Fernández", "A Bellelli", "M Jesús", "ML. Mangoni" ],
      "venue" : "Acta Biomater 2017;47:170-81",
      "citeRegEx" : "163",
      "shortCiteRegEx" : "163",
      "year" : 2017
    }, {
      "title" : "Biofilm inhibitory effect of chlorhexidine conjugated gold nanoparticles against Klebsiella Pneumoniae",
      "author" : [ "A Ahmed", "AK Khan", "A Anwar", "SA Ali", "MR. Shah" ],
      "venue" : "Microb Pathog 2016;98:50-6",
      "citeRegEx" : "164",
      "shortCiteRegEx" : "164",
      "year" : 2016
    }, {
      "title" : "Amoxicillin functionalized gold nanoparticles reverts MRSA resistance",
      "author" : [ "S Kalita", "R Kandimalla", "KK Sharma", "AC Kataki", "M Deka", "J. Kotoky" ],
      "venue" : "Mater Sci Eng C  2016;61:720-7",
      "citeRegEx" : "165",
      "shortCiteRegEx" : "165",
      "year" : 2016
    }, {
      "title" : "Gold nanoparticles make chitosan–streptomycin conjugates effective towards gram-negative bacterial biofilm",
      "author" : [ "H Mu", "Q Liu", "H Niu", "Y Sun", "J. Duan" ],
      "venue" : "RSC Adv",
      "citeRegEx" : "166",
      "shortCiteRegEx" : "166",
      "year" : 2016
    }, {
      "title" : "Silver nanoparticles strongly enhance and restore  2301  S",
      "author" : [ "A Panáček", "M Smékalová", "R Večeřová", "K Bogdanová", "M Röderová", "M Kolář" ],
      "venue" : "Zaidi et al / Nanomedicine: Nanotechnology, Biology, and Medicine",
      "citeRegEx" : "167",
      "shortCiteRegEx" : "167",
      "year" : 2017
    }, {
      "title" : "Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter Baumannii",
      "author" : [ "G Wan", "L Ruan", "Y Yin", "T Yang", "M Ge", "X. Cheng" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "168",
      "shortCiteRegEx" : "168",
      "year" : 2016
    }, {
      "title" : "Antimicrobial silver-filled silica nanorattles with low immunotoxicity in dendritic cells",
      "author" : [ "PriebeM", "Widmer J", "LöwaNS", "AbramSL", "Mottas I", "WoischnigAK" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "169",
      "shortCiteRegEx" : "169",
      "year" : 2017
    }, {
      "title" : "A decomposable silicabased antibacterial coating for percutaneous titanium implant",
      "author" : [ "J Wang", "G Wu", "X Liu", "G Sun", "D Li", "H. Wei" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "170",
      "shortCiteRegEx" : "170",
      "year" : 2017
    }, {
      "title" : "Redox-triggered release of moxifloxacin from mesoporous silica nanoparticles functionalized with disulfide snap-tops enhances efficacy against pneumonic tularemia in mice",
      "author" : [ "BY Lee", "Z Li", "DL Clemens", "BJ Dillon", "AA Hwang", "JI Zink" ],
      "venue" : null,
      "citeRegEx" : "171",
      "shortCiteRegEx" : "171",
      "year" : 2016
    }, {
      "title" : "Composite porous silicon–silver nanoparticles as Theranostic antibacterial agents",
      "author" : [ "T Kim", "GB Braun", "ZG She", "S Hussain", "E Ruoslahti", "MJ. Sailor" ],
      "venue" : "ACS Appl Mater Interfaces",
      "citeRegEx" : "172",
      "shortCiteRegEx" : "172",
      "year" : 2016
    }, {
      "title" : "Green synthesis of rifampicin-loaded copper nanoparticles with enhanced antimicrobial activity",
      "author" : [ "MJ Woźniak-Budych", "Ł Przysiecka", "K Langer", "B Peplińska", "M Jarek", "M Wiesner" ],
      "venue" : "J Mater Sci Mater Med",
      "citeRegEx" : "173",
      "shortCiteRegEx" : "173",
      "year" : 2017
    }, {
      "title" : "A topical antibacterial ointment made of Zn-doped copper oxide nanocomposite",
      "author" : [ "AR Deokar", "Y Shalom", "I Perelshtein", "N Perkas", "A Gedanken", "E. Banin" ],
      "venue" : "J Nanopart Res",
      "citeRegEx" : "174",
      "shortCiteRegEx" : "174",
      "year" : 2016
    }, {
      "title" : "Graphene quantum dot/silver nanoparticle hybrids with oxidase activities for antibacterial application",
      "author" : [ "S Chen", "Y Quan", "YL Yu", "JH. Wang" ],
      "venue" : "ACS Biomater Sci Eng",
      "citeRegEx" : "175",
      "shortCiteRegEx" : "175",
      "year" : 2017
    }, {
      "title" : "A rapid detection method of Brucella with quantum dots and magnetic beads conjugated with different polyclonal antibodies",
      "author" : [ "D Song", "X Qu", "Y Liu", "L Li", "D Yin", "J Li" ],
      "venue" : "Nanoscale Res Lett 2017;12(1):179",
      "citeRegEx" : "176",
      "shortCiteRegEx" : "176",
      "year" : 2017
    }, {
      "title" : "Synthesis of self-assembled spermidine-carbon quantum dots effective against multidrug-resistant bacteria",
      "author" : [ "YJ Li", "SG Harroun", "YC Su", "CF Huang", "B Unnikrishnan", "HJ Lin" ],
      "venue" : "Adv Healthc Mater",
      "citeRegEx" : "177",
      "shortCiteRegEx" : "177",
      "year" : 2016
    }, {
      "title" : "Selective laser ablation of methicillin-resistant staphylococcus aureus with IgG functionalized multi-walled carbon nanotubes",
      "author" : [ "L Mocan", "I Ilie", "FA Tabaran", "C Iancu", "O Mosteanu", "T Pop" ],
      "venue" : "J Biomed Nanotechnol",
      "citeRegEx" : "178",
      "shortCiteRegEx" : "178",
      "year" : 2016
    }, {
      "title" : "A novel covalent approach to bio-conjugate silver coated single walled carbon nanotubes with antimicrobial peptide",
      "author" : [ "AA Chaudhari", "S debNath", "K Kate", "V Dennis", "SR Singh", "OwenDR" ],
      "venue" : "J Nanobiotechnol",
      "citeRegEx" : "179",
      "shortCiteRegEx" : "179",
      "year" : 2016
    }, {
      "title" : "Nanoparticles for transcutaneous vaccination",
      "author" : [ "Hansen S", "Lehr CM" ],
      "venue" : "J Microbial Biotechnol",
      "citeRegEx" : "180",
      "shortCiteRegEx" : "180",
      "year" : 2012
    }, {
      "title" : "Targeted nasal vaccination provides antibody-independent protection against Staphylococcus Aureus",
      "author" : [ "K Misstear", "EA McNeela", "AG Murphy", "JA Geoghegan", "KM O'keeffe", "J Fox" ],
      "venue" : "J Infect Dis 2014;209(9):1479-84",
      "citeRegEx" : "181",
      "shortCiteRegEx" : "181",
      "year" : 2014
    }, {
      "title" : "The perpetual challenge of infectious diseases",
      "author" : [ "Fauci AS", "Morens DM" ],
      "venue" : "Med 2012;366(5):454-61",
      "citeRegEx" : "182",
      "shortCiteRegEx" : "182",
      "year" : 2012
    }, {
      "title" : "Engineering approaches to immunotherapy",
      "author" : [ "MA Swartz", "S Hirosue", "JA. Hubbell" ],
      "venue" : "Sci Transl Med",
      "citeRegEx" : "183",
      "shortCiteRegEx" : "183",
      "year" : 2012
    }, {
      "title" : "Engineering synthetic vaccines using cues from natural immunity",
      "author" : [ "DJ Irvine", "MA Swartz", "GL. Szeto" ],
      "venue" : "Nat Mater",
      "citeRegEx" : "184",
      "shortCiteRegEx" : "184",
      "year" : 2013
    }, {
      "title" : "Generation of protective immunity against Orientia tsutsugamushi infection by immunization with a zinc oxide nanoparticle combined with ScaA antigen",
      "author" : [ "NY Ha", "HM Shin", "P Sharma", "HA Cho", "CK Min", "HI Kim" ],
      "venue" : "J Nanobiotechnol",
      "citeRegEx" : "185",
      "shortCiteRegEx" : "185",
      "year" : 2016
    }, {
      "title" : "Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery",
      "author" : [ "ML Tan", "PF Choong", "CR. Dass" ],
      "venue" : "Peptides",
      "citeRegEx" : "186",
      "shortCiteRegEx" : "186",
      "year" : 2010
    }, {
      "title" : "Tailoring nanocarriers for intracellular protein delivery",
      "author" : [ "Z Gu", "A Biswas", "M Zhao", "Y. Tang" ],
      "venue" : "Chem Soc Rev 2011;40(7):3638-55",
      "citeRegEx" : "187",
      "shortCiteRegEx" : "187",
      "year" : 2011
    }, {
      "title" : "Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens",
      "author" : [ "CH Villa", "T Dao", "I Ahearn", "N Fehrenbacher", "E Casey", "DA Rey" ],
      "venue" : "ACS Nano 2011;5(7):5300-11",
      "citeRegEx" : "188",
      "shortCiteRegEx" : "188",
      "year" : 2011
    }, {
      "title" : "Biomaterials for nanoparticle vaccine delivery systems",
      "author" : [ "P Sahdev", "LJ Ochyl", "JJ. Moon" ],
      "venue" : "Pharm Res",
      "citeRegEx" : "189",
      "shortCiteRegEx" : "189",
      "year" : 2014
    }, {
      "title" : "Protective antibody and CD8+ T-cell responses to the plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine",
      "author" : [ "SA Kaba", "ME McCoy", "TA Doll", "C Brando", "Q Guo", "D Dasgupta" ],
      "venue" : "PLoS One 2012;7(10):e48304",
      "citeRegEx" : "190",
      "shortCiteRegEx" : "190",
      "year" : 2012
    }, {
      "title" : "Facile two-step synthesis of porous antigen-loaded degradable polyelectrolyte microspheres",
      "author" : [ "M Dierendonck", "S De Koker", "C Cuvelier", "J Grooten", "C Vervaet", "JP Remon" ],
      "venue" : "Angew Chem Int Ed",
      "citeRegEx" : "191",
      "shortCiteRegEx" : "191",
      "year" : 2010
    }, {
      "title" : "PRINT: a novel platform toward shape and size specific nanoparticle theranostics",
      "author" : [ "JL Perry", "KP Herlihy", "ME Napier", "JM. DeSimone" ],
      "venue" : "Acc Chem Res",
      "citeRegEx" : "192",
      "shortCiteRegEx" : "192",
      "year" : 2011
    }, {
      "title" : "Rapid and persistent delivery of antigen by lymph node targeting PRINT nanoparticle vaccine carrier to promote humoral immunity",
      "author" : [ "SN Mueller", "S Tian", "JM. DeSimone" ],
      "venue" : null,
      "citeRegEx" : "193",
      "shortCiteRegEx" : "193",
      "year" : 2015
    }, {
      "title" : "Binding, internalization, and antigen presentation of vaccine-loaded Nanoengineered capsules in blood",
      "author" : [ "R De Rose", "AN Zelikin", "AP Johnston", "A Sexton", "SF Chong", "C Cortez" ],
      "venue" : "Adv Mater 2008;20(24):4698-703",
      "citeRegEx" : "194",
      "shortCiteRegEx" : "194",
      "year" : 2008
    }, {
      "title" : "Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform",
      "author" : [ "CMJ Hu", "L Zhang", "S Aryal", "C Cheung", "RH Fang", "L. Zhang" ],
      "venue" : "Proc Natl Acad Sci 2011;108(27):10980-5",
      "citeRegEx" : "195",
      "shortCiteRegEx" : "195",
      "year" : 2011
    }, {
      "title" : "A biomimetic nanosponge that absorbs pore-forming toxins",
      "author" : [ "CMJ Hu", "RH Fang", "J Copp", "BT Luk", "L. Zhang" ],
      "venue" : "Nat Nanotechnol",
      "citeRegEx" : "196",
      "shortCiteRegEx" : "196",
      "year" : 2013
    }, {
      "title" : "Nanoparticle-detained toxins for safe and effective vaccination",
      "author" : [ "CMJ Hu", "RH Fang", "BT Luk", "L. Zhang" ],
      "venue" : "Nat Nanotechnol",
      "citeRegEx" : "197",
      "shortCiteRegEx" : "197",
      "year" : 2013
    }, {
      "title" : "Nanotechnology in vaccine delivery",
      "author" : [ "LJ Peek", "CR Middaugh", "C. Berkland" ],
      "venue" : "Adv Drug Deliv Rev 2008;60(8):915-28",
      "citeRegEx" : "198",
      "shortCiteRegEx" : "198",
      "year" : 2008
    }, {
      "title" : "Reorienting our view of particle-based adjuvants for subunit vaccines",
      "author" : [ "Little SR" ],
      "venue" : "Proc Natl Acad Sci",
      "citeRegEx" : "199",
      "shortCiteRegEx" : "199",
      "year" : 2012
    }, {
      "title" : "Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice",
      "author" : [ "Q Zhu", "C Egelston", "S Gagnon", "Y Sui", "IM Belyakov", "DM Klinman" ],
      "venue" : "J Clin Invest",
      "citeRegEx" : "200",
      "shortCiteRegEx" : "200",
      "year" : 2010
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Rapid development of antibiotic resistance in bacteria, coupled with slow and declining development of new antibiotics, has resulted in an arms race between therapeutic development and emergence of antibiotic resistance in bacteria.(1) Pathogens gain resistance against antibiotics by different mechanisms like alterations in membrane permeability, multidrug efflux pumps development, deoxyribonucleic acid (DNA) alterations, drug degrading activity of enzymes as well as longer intracellular residence durations, where therapeutic level of drugs cannot be easily achieved,(2) consequently requiring higher doses, and repeated administrations of drugs and eventually leading to toxicity or adverse side effects.",
      "startOffset" : 232,
      "endOffset" : 235
    }, {
      "referenceID" : 5,
      "context" : "As stated by Paul Erlich the “concept of magic bullet” that is “the aim of drug targeting is to deliver drugs to the right place, at the right concentration, and for the proper length of time”.(6) In the last 10 years, nanotechnology has gained significant momentum.",
      "startOffset" : 193,
      "endOffset" : 196
    }, {
      "referenceID" : 6,
      "context" : "Use of nanoparticles (NPs) has increased more than four-fold and current researches are primarily emphasizing the antimicrobial activity of NPs, predominantly against drug-resistant bacteria.(7) Moreover, use of NPs as a drug carrier can support and complement traditional antibiotics.",
      "startOffset" : 191,
      "endOffset" : 194
    }, {
      "referenceID" : 10,
      "context" : "irrespective of the type of drug and pathogen.(11) Moreover, antimicrobial potential of NPs has been extensively explored and nanoscale materials like inorganic ions and polymers are found to have potent antibiotic activity themselves.",
      "startOffset" : 46,
      "endOffset" : 50
    }, {
      "referenceID" : 14,
      "context" : "Therefore, it becomes difficult for bacterial cells to acquire resistance against NPs mediated antibacterial treatment.(15) NPs as delivery systems allow the targeted delivery of drugs as well as sustained and controlled release let them reach the intracellular therapeutic level of drugs.",
      "startOffset" : 119,
      "endOffset" : 123
    }, {
      "referenceID" : 15,
      "context" : "Other advantages of NP delivery systems, includes, enhanced drug solubility, concurrent delivery of multiple drugs, prolonged systemic circulation as validated by many studies.(16,17) As a result of this, many NP-based treatments including NPs as vaccine delivery systems have been endorsed to treat variety of infections and several others are currently undergoing through the phases of pre-clinical and clinical tests.",
      "startOffset" : 176,
      "endOffset" : 183
    }, {
      "referenceID" : 16,
      "context" : "Other advantages of NP delivery systems, includes, enhanced drug solubility, concurrent delivery of multiple drugs, prolonged systemic circulation as validated by many studies.(16,17) As a result of this, many NP-based treatments including NPs as vaccine delivery systems have been endorsed to treat variety of infections and several others are currently undergoing through the phases of pre-clinical and clinical tests.",
      "startOffset" : 176,
      "endOffset" : 183
    }, {
      "referenceID" : 45,
      "context" : "Good compatibility as well as biodegradability are the foremost advantages of using them.(46) Their constituent compounds can be easily degraded into biologically tolerated molecules, which are then metabolized via the Krebs cycle.",
      "startOffset" : 89,
      "endOffset" : 93
    }, {
      "referenceID" : 46,
      "context" : "Furthermore, both hydrophilic and hydrophobic drugs can be carried by them.(47) There are certain limitations, like low loading efficacy, drug loss during storage and delivery and they are relatively unstable.",
      "startOffset" : 75,
      "endOffset" : 79
    }, {
      "referenceID" : 2,
      "context" : "Besides, their hydrophilic/hydrophobic characteristics allow their uptake by opsonisation followed by rapid degradation.(3,33,48)",
      "startOffset" : 120,
      "endOffset" : 129
    }, {
      "referenceID" : 32,
      "context" : "Besides, their hydrophilic/hydrophobic characteristics allow their uptake by opsonisation followed by rapid degradation.(3,33,48)",
      "startOffset" : 120,
      "endOffset" : 129
    }, {
      "referenceID" : 47,
      "context" : "Besides, their hydrophilic/hydrophobic characteristics allow their uptake by opsonisation followed by rapid degradation.(3,33,48)",
      "startOffset" : 120,
      "endOffset" : 129
    }, {
      "referenceID" : 48,
      "context" : "These are the most extensively explored NPs.(49)",
      "startOffset" : 44,
      "endOffset" : 48
    }, {
      "referenceID" : 51,
      "context" : "Natural polymers include, albumin, alginate or chitosan(50,51) Chitosan is most widely used due to its easy modification, muco-adhesive and antimicrobial properties.(52)",
      "startOffset" : 165,
      "endOffset" : 169
    }, {
      "referenceID" : 3,
      "context" : "Below which, they are an inert material, and above them the chains become hydrophobic, which results in their aggregation and precipitation.(4,53,54) The hydrophobic fragments form the inner core of the sphere, while the hydrophilic ones form the outer shell.",
      "startOffset" : 140,
      "endOffset" : 149
    }, {
      "referenceID" : 52,
      "context" : "Below which, they are an inert material, and above them the chains become hydrophobic, which results in their aggregation and precipitation.(4,53,54) The hydrophobic fragments form the inner core of the sphere, while the hydrophilic ones form the outer shell.",
      "startOffset" : 140,
      "endOffset" : 149
    }, {
      "referenceID" : 53,
      "context" : "Below which, they are an inert material, and above them the chains become hydrophobic, which results in their aggregation and precipitation.(4,53,54) The hydrophobic fragments form the inner core of the sphere, while the hydrophilic ones form the outer shell.",
      "startOffset" : 140,
      "endOffset" : 149
    }, {
      "referenceID" : 3,
      "context" : "Like other organic NPs, polymeric micelles also exhibit low toxicity risk as they disassemble in single polymer chains which can be easily eliminated without any toxicity.(4,55)",
      "startOffset" : 171,
      "endOffset" : 177
    }, {
      "referenceID" : 54,
      "context" : "Like other organic NPs, polymeric micelles also exhibit low toxicity risk as they disassemble in single polymer chains which can be easily eliminated without any toxicity.(4,55)",
      "startOffset" : 171,
      "endOffset" : 177
    }, {
      "referenceID" : 32,
      "context" : "Due to their unique size-dependent properties, lipid NPs offer the possibility to develop new therapeutics.(33,48)",
      "startOffset" : 107,
      "endOffset" : 114
    }, {
      "referenceID" : 47,
      "context" : "Due to their unique size-dependent properties, lipid NPs offer the possibility to develop new therapeutics.(33,48)",
      "startOffset" : 107,
      "endOffset" : 114
    }, {
      "referenceID" : 37,
      "context" : "They are prepared by the reduction of the metallic salt (silica/silver/ gold/aluminium/titanium) with a reducing agent(56,57) and, depending on the reaction conditions like temperature, pH, reduction time or reducing agent concentration, their characteristics can be modified.(38,43,58) For the purpose of drug delivery, selection of the reducing agent is a critical task, as it acts as a link between the NP's surface and the drug or biomolecule of interest.",
      "startOffset" : 276,
      "endOffset" : 286
    }, {
      "referenceID" : 42,
      "context" : "They are prepared by the reduction of the metallic salt (silica/silver/ gold/aluminium/titanium) with a reducing agent(56,57) and, depending on the reaction conditions like temperature, pH, reduction time or reducing agent concentration, their characteristics can be modified.(38,43,58) For the purpose of drug delivery, selection of the reducing agent is a critical task, as it acts as a link between the NP's surface and the drug or biomolecule of interest.",
      "startOffset" : 276,
      "endOffset" : 286
    }, {
      "referenceID" : 57,
      "context" : "Moreover, loading capacity, drug release, aggregation of NPs as well as the antimicrobial action of drugs is also influenced by the choice of reducing agent.(59) Compared with organic NPs, metallic NPs are smaller with more loading capacity, and some with antimicrobial properties can also be used as naked NPs.",
      "startOffset" : 157,
      "endOffset" : 161
    } ],
    "year" : 2017,
    "abstractText" : "With the arrival of antibiotics 70 years ago, meant a paradigm shift in overcoming infectious diseases. For decades, drugs have been used to treat different infections. However, with time bacteria have become resistant to multiple antibiotics, making some diseases difficult to fight. Nanoparticles (NPs) as antibacterial agents appear to have potential to overcome such problems and to revolutionize the diagnosis and treatment of bacterial infections. Therefore, there is significant interest in the use of NPs to treat variety of infections, particularly caused by multidrug-resistant (MDR) strains. This review begins with illustration of types of NPs followed by the literature of current research addressing mechanisms of NPs antibacterial activity, steps involved in NP mediated drug delivery as well as areas where NPs use has potential to improve the treatment, like NP enabled vaccination. Besides, recently emerged innovative NP platforms have been highlighted and their progress made in each area has been reviewed. © 2017 Elsevier Inc. All rights reserved.",
    "creator" : "Elsevier"
  }
}